Explorations into host defense against Plasmodium falciparum: mechanistic and structure-function studies of antimalarial chemokines by Love, Melissa Suzanne
University of Pennsylvania
ScholarlyCommons
Publicly Accessible Penn Dissertations
1-1-2014
Explorations into host defense against Plasmodium
falciparum: mechanistic and structure-function
studies of antimalarial chemokines
Melissa Suzanne Love
University of Pennsylvania, mlove73085@gmail.com
Follow this and additional works at: http://repository.upenn.edu/edissertations
Part of the Biochemistry Commons, Parasitology Commons, and the Pharmacology Commons
This paper is posted at ScholarlyCommons. http://repository.upenn.edu/edissertations/1352
For more information, please contact libraryrepository@pobox.upenn.edu.
Recommended Citation
Love, Melissa Suzanne, "Explorations into host defense against Plasmodium falciparum: mechanistic and structure-function studies of
antimalarial chemokines" (2014). Publicly Accessible Penn Dissertations. 1352.
http://repository.upenn.edu/edissertations/1352
Explorations into host defense against Plasmodium falciparum:
mechanistic and structure-function studies of antimalarial chemokines
Abstract
Antimicrobial peptides (AMPs) are small (2-8kDa) peptides that have remained an important part of innate
immunity over evolutionary time. AMPs vary greatly in sequence and structure, but display broad-spectrum
activity against bacteria, yeast, and fungi via direct perturbation of the pathogen membrane. AMPs are
typically amphipathic, and contain 2-4 positively charged amino acid residues. It has been previously shown
that many chemokines also display AMP activity, both via their canonical function recruiting immune cells to
the site of an infection and by direct interaction with the pathogen itself. Many antimicrobial chemokines have
the same tertiary structure: an N-terminal loop responsible for receptor recognition; a three-stranded
antiparallel β-sheet domain that provides a stable scaffold; and a C-terminal α-helix that folds over the β-sheet
and helps to stabilize the overall structure. The α-helix of these chemokines tends to be amphipathic and
retains AMP activity on its own. The work presented here focuses on two antimicrobial chemokines - platelet
factor 4 (CXCL4/PF4) and macrophage inflammatory protein-3α (CCL20/MIP-3α) - and shows that they
have activity against the malaria parasite. Chapter 2 details the exploration into the mechanism of action of
PF4 against P. falciparum, and the translation of this mechanism to small molecules that mimic antimicrobial
peptides. Additionally, this antimalarial activity is also present in a mouse model of malaria. Chapter 3 focuses
on finding additional chemokines with antimalarial activity, and explores the structure-function relationship
between the conserved domains and how they modulate i) the antimalarial activity, and ii) provide a
protective scaffold to prevent harm to host cells. We provide evidence that PF4 and small molecule mimics of
AMPs kill parasites by exclusively lysing the digestive vacuole. Furthermore, the C-terminal α-helix of PF4 and
CCL20 are the active components of each chemokine, and are necessary for parasite killing. The N-terminal
loop is necessary to stabilize the tertiary structure of each chemokine, providing a stable scaffold that aides in
the selectivity to protect host cells. Taken together, these data suggest that antimicrobial chemokines and
small molecule mimics may provide an interesting scaffold and mechanism for potential therapeutics for the
fight against malaria.
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ABSTRACT 
EXPLORATIONS INTO HOST DEFENSE AGAINST PLASMODIUM FALCIPARUM: 
MECHANISTIC AND STRUCTURE-FUNCTION STUDIES OF ANTIMALARIAL 
CHEMOKINES 
Melissa Suzanne Love 
Doron C. Greenbaum, PhD 
Antimicrobial peptides (AMPs) are small (2-8kDa) peptides that have remained an 
important part of innate immunity over evolutionary time. AMPs vary greatly in sequence 
and structure, but display broad-spectrum activity against bacteria, yeast, and fungi via 
direct perturbation of the pathogen membrane. AMPs are typically amphipathic, and 
contain 2-4 positively charged amino acid residues. It has been previously shown that 
many chemokines also display AMP activity, both via their canonical function recruiting 
immune cells to the site of an infection and by direct interaction with the pathogen itself. 
Many antimicrobial chemokines have the same tertiary structure: an N-terminal loop 
responsible for receptor recognition; a three-stranded antiparallel β-sheet domain that 
provides a stable scaffold; and a C-terminal α-helix that folds over the β-sheet and helps 
to stabilize the overall structure. The α-helix of these chemokines tends to be 
amphipathic and retains AMP activity on its own. The work presented here focuses on 
two antimicrobial chemokines – platelet factor 4 (CXCL4/PF4) and macrophage 
inflammatory protein-3α (CCL20/MIP-3α) – and shows that they have activity against the 
malaria parasite. Chapter 2 details the exploration into the mechanism of action of PF4 
against P. falciparum, and the translation of this mechanism to small molecules that 
mimic antimicrobial peptides. Additionally, this antimalarial activity is also present in a 
mouse model of malaria. Chapter 3 focuses on finding additional chemokines with 
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antimalarial activity, and explores the structure-function relationship between the 
conserved domains and how they modulate i) the antimalarial activity, and ii) provide a 
protective scaffold to prevent harm to host cells. We provide evidence that PF4 and 
small molecule mimics of AMPs kill parasites by exclusively lysing the digestive vacuole. 
Furthermore, the C-terminal α-helix of PF4 and CCL20 are the active components of 
each chemokine, and are necessary for parasite killing. The N-terminal loop is 
necessary to stabilize the tertiary structure of each chemokine, providing a stable 
scaffold that aides in the selectivity to protect host cells. Taken together, these data 
suggest that antimicrobial chemokines and small molecule mimics may provide an 
interesting scaffold and mechanism for potential therapeutics for the fight against 
malaria. 
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CHAPTER 1: Introduction 
1.1 Malaria 
Malaria continues to be a large global health burden, particularly on the African 
continent, where 90% of malaria deaths occur, most of which are in children under the 
age of 5. The WHO estimates there were 207 million new cases leading to over 600,000 
deaths in 2012 [1]. Coupled with the impact of tuberculosis and HIV/AIDS, malaria has 
had severely negative consequences for the socio-economics of Africa [2]. Malaria is 
characterized by cyclic recurrent fevers, metabolic acidosis, respiratory distress, and 
anemia. Severe cases can lead to severe anemia, hemoglobinuria, acute kidney failure, 
hypoglycemia, and cerebral symptomology [3].  
 The disease is caused by protozoan parasites of the Plasmodium genus, with 
four species that infect humans through the bite of an Anopheles mosquito. The most 
deadly of these four species is P. falciparum, which is responsible for the majority of 
malaria fatalities. P. falciparum, the most recently evolved human-infecting species of 
malaria parasites, is the most virulent; this is likely due to its ability to vastly remodel the 
host red blood cell upon invasion. The most significant adaptation P. falciparum imparts 
to its host cell are exported surface proteins, which cause the infected cells to adhere to 
the endothelial walls, leading to obstructions of the microvasculature in organs such as 
the lungs, kidneys, and brain [4]. 
 Current malaria control efforts consist of two primary methods: vector control 
(insecticide-treated nets and residual indoor spraying), and chemotherapy. Significant 
effort has been put into developing a malaria vaccine, but after multiple decades of 
development, the most promising vaccine (RTS,S plus adjuvant AS01) has only shown 
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modest short-term effectiveness [5, 6]. Drug treatment of malaria also faces a myriad of 
problems, as resistance to most antimalarials is spreading throughout the endemic 
regions, rendering many of them ineffective. Chloroquine, which kills parasites by 
inhibiting the detoxification of heme, was the mainstay treatment for almost 50 years due 
to its effectiveness and low cost. However, resistance started within 20 years of its 
implementation, and the spread of resistant strains has left the effectiveness of 
chloroquine all but nullified. The combination antimalarial sulfadoxine/pyrimethamine, 
which targets two enzymes in the folate metabolism pathway, and other similar drugs 
have produced resistant parasites at an even faster rate [7]. 
 Modern malaria chemotherapy relies on artemisinin-based combination therapies 
(ACTs). The benefit of a combination of two drugs with different mechanisms of action is 
a lower propensity to induce resistance – a necessity in the fight to eradicate malaria. 
The mechanism of artemisinin is still being investigated, but the site is believed to be in 
the parasite digestive vacuole [8]. ACTs are currently effective in areas where there is 
rampant resistance to other antimalarials, though areas of artemisinin monotherapy have 
emerging resistance [9]. The current state of affairs in managing the malaria burden 
indicate that new therapeutics with novel targets are needed in the pipeline, ideally with 
a low propensity to cause resistance [10]. 
1.2 The Plasmodium falciparum life cycle 
Plasmodium falciparum is a protozoan parasite with a complicated lifecycle involving two 
different host organisms. Female mosquitoes of the Anopheles gambiae species ingest 
P. falciparum gametocytes from an infected human when taking a blood meal. In the 
mosquito gut, the gametocytes transition into male and female gametes, which then fuse 
to form a zygote. The zygote develops into an ookinete that penetrates the gut wall to 
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form a sporozoite-filled oocyst. This oocyst ruptures, and the released sporozoites move 
to the insect’s saliva, where they wait to be injected into a human upon the mosquito’s 
next blood meal. 
 When sporozoites are injected into a human host’s blood, they first migrate to the 
liver, whereupon they go through multiple stages of development over several weeks. 
The final hepatocytic stage, merozoites, are released en masse into the blood stream. 
DV	  
DV	  
DV	  
DV	  
Figure 1.1: The malaria parasite erythrocytic pathway. Merozoite parasites invade the erythrocyte 
(RBC) and develop into ring stage parasites within the parasitophorous vacuole (PV). The peak of the 
parasite’s metabolic activity occurs during the growing trophozoite stage, during which host cell 
cytoplasm is endocytosed and large-scale hemoglobin proteolysis in carried out within the digestive 
vacuole (DV). In addition, the parasite sets up a complex secretory pathway during this stage for 
delivering proteins to the PV and host cell. During the schizont stage multiple rounds of nuclear division 
occur, which results in the formation of daughter merozoites. At roughly 48 hrs post infection (for P. 
falciparum), the parasite ruptures from the host cell. PVM, parasitophorous vacuole membrane; N, 
nucleus; Mer, merozoite. 
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The merozoites infect red blood cells (RBCs), beginning the intraerythrocytic cycle 
responsible for the pathology of malaria. The newly invaded merozoites develop into the 
ring stage, which then become metabolically active trophozoites approximately 24 hours 
post RBC invasion. Trophozoites develop into schizonts, which replicate their DNA and 
form 16-32 daughter merozoites via cellular segmentation.  At 48 hours post invasion, 
the merozoites rupture, or egress, out of the erythrocyte and go on to infect new cells, 
thus beginning the cycle again (Figure 1.1) [11]. 
During parasite invasion, Plasmodium falciparum causes invagination of the RBC 
membrane, forming a double membrane derived vacuolar space termed the 
parasitophorous vacuole (PV). The parasite spends its entire time in this vacuole while it 
is within the RBC, until egress, digesting ~75% of the host cell’s hemoglobin [12-14]. 
Host cell cytoplasm begins to be taken up by the parasite in mid-ring stage via 
specialized structures called cytostomes. The acidified (pH 4.5-5.5) vesicles that bud off 
of the cytostome digest hemoglobin. As more form, they eventually coalesce into a large 
digestive vacuole (DV) in the early trophozoite stage. This site of hemoglobin digestion, 
and subsequent formation of hemozoin – an insoluble polymer of hematin – is a target 
for many antimalarials [15]. 
1.3 Antimicrobial peptides 
Antimicrobial peptides (AMPs), also known as host defense peptides (HDPs), play a 
central role in the innate immune system [16-18]. They are comprised of two types: 
ribosomally and nonribosomally synthesized peptides. Over 1000 AMPs have been 
identified to date, and they vary greatly in length (12-80 residues), amino acid sequence, 
and three-dimensional structure [19]. Most AMPs are either α-helical (e.g. magainin and 
cecropin), disulfide-rich β-sheets (e.g. bactenecin and defensin), or an extended 
5	  
	  
structure (e.g. indolicidin) [20]. AMPs are particularly important in organisms that lack an 
adaptive immune response based on T-cells and antibodies, and furthermore AMPs 
display broad-spectrum activity against bacteria, fungi, protozoa, and even viruses, 
which has prompted development of AMP-based antibiotics [17]. 
 Though they are vastly different in sequence and structure, the common features 
shared among AMPs include highly amphipathic topologies in which the hydrophilic and 
hydrophobic side chains segregate onto distinct or opposing faces or regions of the 
overall structure. Figure 1.2 demonstrates this facial amphipathicity in Magainin 2 [21]. 
Numerous studies with linear and cyclic peptides suggest that the physicochemical 
properties of AMPs, 
rather than a specific 
sequence or structure, 
are responsible for their 
activities. The general 
theory of the AMP 
mechanism of action is 
via insertion into and 
eventual disruption of the pathogen cytoplasmic membrane, which causes pathogen 
death. The amphipathic topology is believed to be essential for this membrane 
interaction [17]. 
 The basis of the cytotoxic activity and pathogen specificity of these cationic and 
amphipathic AMPs has been greatly studied in bacteria. The specificity for bacteria over 
mammalian (host) cells is likely due to the fundamental differences in membrane 
structure and characteristics: bacteria have a large proportion of negatively charged 
phospholipid head groups on the surface of their membranes, while the outer leaflet of 
Figure 1.2: Magainin 2 shown with cationic groups in blue and 
nonpolar groups in green.  The peptide backbone is shown as a 
yellow ribbon (left) side view and end view (right) highlights the spatial 
amphipathic distribution of cationic and nonpolar amino acid side 
chains that confers the mechanism of action against membranes. 
Adapted from Som, A., et al., Synthetic mimics of antimicrobial 
peptides. Biopolymers, 2008. 90(2): p. 83-93. Reprinted with 
permission. 
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animal cells is composed mainly of neutral lipids [17]. The presence of cholesterol in 
animal cell membranes also appears to reduce AMP activity.  
There have been several mechanisms proposed for this process of cell killing 
[22-26], which occurs within minutes after bacteria are exposed to lethal doses of 
peptide. It appears that AMPs bind to the membrane surface in a non-cooperative 
fashion, and then aggregate when a threshold concentration is achieved, leading to 
rapid membrane permeabilization. Membrane permeabilization is associated with a 
variety of other events including membrane depolarization, leakage of cellular 
metabolites, loss of compositional integrity due to enhanced membrane flip-flopping, and 
translocation of peptides to the cytoplasm where additional targets, such as RNA, DNA, 
and various enzymes, can be encountered [27]. It is unclear which of these events are 
primarily responsible for bacterial killing, and may depend on the peptide and the 
bacterium [28]. It is also worth noting that AMPs have remained an effective weapon 
against bacterial infection over evolutionary time, indicating that their mechanism of 
action thwarts bacterial responses that normally lead to resistance against toxic 
substances. This premise is supported by data showing that no appreciable resistance 
to AMPs occurs after multiple passages of bacteria in the presence of sublethal 
concentrations of the peptides [29-31]. 
1.4 Synthetic mimics of antimicrobial peptides 
Because of difficulties with tissue distribution and toxicity of AMPs, as well as the high 
cost of synthesis and purification, a library of small molecule synthetic mimics of 
antimicrobial peptides (smAMPs) has been developed [31, 32]. These small molecules 
mimic the amphipathic structure of AMPs, and display good broad-spectrum activity 
against bacteria while having low toxicity in animals. The Greenbaum laboratory has 
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tested well over 1000 of these compounds, demonstrating that many of them kill P. 
falciparum in culture with IC50s in the low nanomolar range, and display a high degree 
of safety [33]. An added advantage of these compounds is that they are small 
molecules, and are thus able to be more easily chemically modified to optimize 
specificity, stability, and tissue distribution. 
1.5 Antimicrobial chemokines 
Chemokines are a superfamily of chemotactic proteins that have many roles in cellular 
functions, such as inflammation, development, angiogenesis, and immunity [34-36]. 
Almost 50 human chemokines have been identified to date, along with 20 different G-
protein-coupled 7-pass transmembrane receptors (GPCRs) that control the various 
downstream effects [37]. Although there is some redundancy among which receptors 
certain chemokines can activate (or antagonize), each chemokine differs in stimuli that 
induce their release, cells that produce them, binding affinities, and biological potencies 
and efficacies [38, 39]. 
 With regard to function, chemokines can be divided into inflammatory (inducible) 
chemokines or homeostatic (constitutively expressed) chemokines. The inflammatory 
chemokines play a key role in innate immune response by attracting a diverse array of 
effector leukocytes to inflammatory sites: neutrophils, monocytes/macrophages, 
dendritic cells, and natural killer cells. Homeostatic chemokines have important roles in 
migration of antigen-presenting cells, lymphocytes into the lymph node, and effector T 
cells reaching tissues that contain their cognate antigen, all of which are crucial in the 
adaptive immune response [39]. 
Chemokines are small (8-12 kDa), and have a remarkably similar structure 
consisting of an N-terminal loop necessary for receptor activation, a central domain 
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comprised of 3 antiparallel β-strands that provide a stable scaffold, and a C-terminal α-
helix that folds across the β-sheet to stabilize the overall structure (Figure 1.3) [40]. 
Chemokines have four conserved cysteines (two in the N-terminal loop, and 2 in the β-
sheet) that form two essential disulfide bonds (Cys1-Cys3 and Cys2-Cys4). Chemokines 
are traditionally divided into four groups based on the positioning of the first two 
cysteines: C, CC, CXC, and CX3C, where X is any non-cysteine amino acid [36, 37, 41]. 
 
In addition to the roles that chemokines play in immunity through cell trafficking, 
many chemokines also have direct microbicidal activity [40, 42-46]. These antimicrobial 
chemokines are expressed directly in the bloodstream, and therefore necessarily have 
Figure 1.3: Topology of a typical chemokine. The N-terminal loop, which is responsible for receptor 
recognition, is restrained by two disulfide bonds (in yellow). This is followed by a short turn of a 310 helix 
that leads to a three-stranded antiparallel β-sheet. The C-terminal α-helix folds over the β-sheet and 
helps to stabilize the overall tertiary structure. Reprinted from Nguyen, L.T. and H.J. Vogel, Structural 
perspectives on antimicrobial chemokines. Front Immunol, 2012. 3: p. 384. 
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low host toxicity. This is in contrast to classical AMPs, which are typically expressed in 
phagocytes or on mucosa. Because chemokines have a highly conserved tertiary 
structure, examining the key structure-function relationships in antimicrobial chemokines 
may deconvolute their biological role in host defense, and may provide insights into new 
therapeutics against drug-resistant pathogens with minimal host toxicity. 
1.6 Host defense activity against malaria 
The pathogenesis of malaria is modulated both positively and negatively by many 
human cell types in blood including monocytes, neutrophils and platelets [47-52]. While 
platelets have long been known to interact cooperatively with erythrocytes in 
thrombogenesis, both generally and in the specific case of sickle cell disease [53], only 
recently have platelets been shown to bind infected erythrocytes and kill intracellular 
malaria parasites [54]. Previous studies have suggested that thrombocytopenia is a poor 
prognostic marker in malaria [55] and is significantly associated with cerebral malaria 
[56, 57].  
Mature platelet factor 4 (PF4), or CXCL4, is a 70 amino acid protein. It exists as 
a homotetramer in solution, and like other antimicrobial chemokines, consists of an N-
terminal cytokine domain, a central domain responsible for tetramerization, and a C-
terminal domain that binds heparin and also can act as an AMP [46]. PF4 was the first 
characterized chemokine [58], though unlike other chemokines, PF4 does not have 
strong chemotactic properties and does not interact with common chemokine receptors 
except human CXCR3B, an alternatively-spliced CXCR3 [59]. PF4 is a cationic 
molecule, especially in its tetrameric state, with high affinity for heparin and other large, 
negatively-charged molecules [60]. Upon platelet activation, PF4 is released from 
platelet alpha-granules in high local concentrations, up to 100 µM proximal to a clot [61]. 
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PF4 has been implicated in both inflammation [62, 63] and thrombosis [64]. PF4 
released from activated platelets forms complexes with endogenous 
glycosaminoglycans on the surface of platelets [65] and monocytes [65] and likely on 
other hematopoietic and vascular cells. Mice that are knockout for the cxcl4 gene [64] 
(deficient in PF4 (PF4 KO)) or overexpress human PF4 (hPF4+) have proven to be 
important tools in understanding in vivo PF4 biology during thrombosis and 
megakaryopoiesis [66, 67].  
Conversely, Srivastava et al. have recently shown that PF4 may have detrimental 
effects in the pathogenesis of cerebral malaria [62]. A knockout PF4 mouse model 
infected with P. berghei ANKA had improved survival compared to their wild-type 
littermates. Further, a CXCR3 knockout mouse had 100% survival 10 days after 
infection, suggesting that the effects of PF4 on the cerebral symptomology was 
modulated through its chemokine domain. It is unclear whether these observations are 
clinically relevant to cerebral malaria in humans, given that this murine model is 
complicated by severe inflammation in the brain and CNS, unlike human cerebral 
malaria in which little, if any, inflammation is seen [68-70]. As human cerebral malaria is 
a consequence of intravascular sequestration of infected erythrocytes in the brain 
vessels and capillaries, rather than increased inflammation, it is unlikely that human PF4 
mediates increased inflammation during this disease process. Murine models of cerebral 
malaria are further complicated by the marked accumulation of leukocytes and platelets 
in the brain venules and capillaries, a phenomenon not seen in human pathology [70]. 
Human macrophage-inflammatory protein-3α (MIP-3α), or CCL20 is a 70 amino 
acid, 8-kDa protein. It has been linked to numerous diseases, such as cancer, 
rheumatoid arthritis, and diseased periodontal issues [71-73]. CCL20 exclusively binds 
the CCR6 receptor, and interestingly, is the only chemokine that will bind it [74]. 
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Surprisingly, the human β-defensins, β-defensin-1 and β-defensin-2, can also bind and 
activate CCR6 [75]. CCL20 and the human β-defensins have no obvious amino acid 
sequence homology, but there are many structural similarities between them that may 
explain the overlap between their chemotactic and microbicidal activities [76]. CCL20 
and its amphipathic C-terminus have both been shown to have antimicrobial activity 
against E. coli and S. aureus [36, 76, 77].  
In this work, I show that the CXC chemokine CXCL4/PF4 is active against P. 
falciparum at an IC50 of 5-10 µM (Chapters 2 and 3). Chapter 2 focuses on mechanistic 
studies of the direct microbicidal activity of PF4 against the malaria parasite. Chapter 3 
focuses on a closer investigation of the structure-function relationship of the various 
domains of antimicrobial chemokines. In addition to platelet factor 4 (PF4), I also show 
that the CC chemokine CCL20/MIP-3α is potent against P. falciparum (IC50 of ~5 µM), 
and that the hemolytic potential, or host toxicity, is modulated by the tertiary structure. 
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CHAPTER 2: Platelet Factor 4 Activity Against Plasmodium 
falciparum and its Translation to Nonpeptidic Mimics as a New 
Class of Antimalarials* 
2.1 Introduction 
Malaria is a devastating disease and continues to be a global health burden, causing 
significant morbidity and mortality [78]. The pathogenesis of malaria is modulated both 
positively and negatively by many human cell types in blood including monocytes, 
neutrophils and platelets [47-52]. Recently platelets have been shown to bind infected 
erythrocytes and kill intracellular malaria parasites [54]. Previous studies have 
suggested that thrombocytopenia is a poor prognostic marker in malaria [55] and is 
associated with cerebral malaria [56, 57]. We therefore pursued the hypothesis that host 
cells found in the bloodstream that are known to secrete proteins with host defense 
peptide (HDP) activity [43, 54] could contribute to the host’s control of malaria parasite 
proliferation in the blood stage.  
HDPs play a central role in the innate immune system [16-18, 79]. HDPs display 
broad-spectrum action against bacteria, fungi, protozoa, and viruses, which has 
promoted their use as new leads for developing antibiotics [79]. A unifying characteristic 
of HDPs is an amphipathic topology in which the cationic and hydrophobic side chains 
segregate onto opposing faces of the overall folded molecule. It is thought that the 
*The text of this chapter has been published (Love et al. Platelet Factor 4 Activity 
against P. falciparum and Its Translation to Nonpeptidic Mimics as Antimalarials. Cell 
Host Microbe, 2012. 12(6): p. 815-23.) It is printed here with permission. 
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physicochemical properties of HDPs, rather than any specific sequence or structure, are 
responsible for their activities. HDPs are thought to bind the membrane surface in a non-
cooperative fashion and then aggregate once a threshold concentration is reached 
causing membrane permeabilization [22-24, 26, 80]. It is believed that amphipathic 
topology is essential for insertion into and disruption of membranes leading to pathogen 
death. From this background, we hypothesized that naturally occurring bloodstream 
HDPs especially from platelets might have the ability to kill P. falciparum early in 
erythrocytic infection. 
2.2 Results 
Identification of human platelet factor 4 (hPF4) as an antiparasitic HDP that kills P. 
falciparum via lysis of the parasite DV 
A screen of HDPs found in the bloodstream, secreted by a variety of cells including 
platelets, neutrophils, or lymphocytes, was performed to assess their anti-parasitic 
activity (Figure 2.1). This screen revealed that several proteins killed P. falciparum in 
vitro without affecting the host erythrocyte. Most notably, hPF4 showed high potency 
against P. falciparum with an IC50 of 4.2 µM and no significant hemolysis. Considering 
local concentrations of hPF4 have been reported to reach at least 280 µM surrounding 
activated platelets [81], the antiparasitic IC50 of hPF4 has in vivo relevance. Platelets 
harvested from wild-type (WT), mouse PF4 (mPF4) knock-out (mPF4 KO), or 
overexpressing hPF4 (hPF4+) mice were tested against P. falciparum in culture with 
recombinant mPF4 and hPF4 as controls (Figure 2.2). Because there is no evidence to 
suggest that mouse platelets bind to or are activated by human infected erythrocytes, 
platelets were pre-activated with AYP prior to their addition to parasite cultures. Pre-
activated WT and hPF4+ mouse platelets were able to kill P. falciparum in culture, while  
14	  
	  
 
Un
tre
ate
d
500
nM
 AS
Me
litti
n
RA
NT
ES hP
F4
FP
-A
FP
-B
HN
P-1
HN
P-2
La
cto
fer
rin
LL-
37
Lym
ph
ota
ctin
!
"!
#!!
% Parasite Survival
% Hemolysis
"!
#!!
%
 P
ar
as
ite
 S
ur
viv
al
%
 H
em
oly
sis
!"#$%&'()*'Figure 2.1 
Figure 2.1: Screen of human HDPs found in blood for P. falciparum killing and hemolysis. All 
HDPs were tested at 15 µM. Regulated upon Activation, Normal T-cell Expressed, and Secreted 
(RANTES); hPF4; Fibrinopeptide-A (FP-A); Fibrinopeptide-B (FP-B); Human Neutrophil Peptides 1 and 2 
(HNP-1; HNP-2); Cathelicidin (LL-37). Parasite survival was normalized to an untreated control. 
Artesunate (500 nM) and the HDP melittin (15 µM) were used as positive controls for parasite death 
without and with hemolysis, respectively. Data shown are means ± SEM. 
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Figure 2.2: PF4-containing platelets kill P. falciparum in vitro. Parasite-infected erythrocytes were 
incubated for 24 hours with 2.5 x 108 platelets from either littermate WT, PF4 KO, or hPF4+ mice in the 
presence or absence of 5 µM AYP to induce platelet activation. Parasite survival assayed by flow 
cytometry using SYTOX green as a measurement of DNA content and normalized to an untreated 
control. Recombinant hPF4 and mPF4 (10 µM) were used as positive controls. Data shown are means ± 
SEM. 
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littermate PF4 KO platelets showed no killing capacity. Thus it appears that PF4 is a 
major antimalarial component of activated platelets. 
 As membrane perturbation is an established mechanism of action for HDPs [25, 
79, 82-84], we examined the integrity of potential target parasite membranes upon hPF4 
treatment. Since hPF4 had little hemolytic capability we reasoned the erythrocyte 
integrity was not significantly compromised. Parasite plasma membrane (PPM) potential 
assays showed no discernible loss of potential following 4 hours of hPF4 exposure 
(Figure 2.3). Next the integrity of established intracellular parasite organelle targets, 
including the mitochondria and lysosome-like digestive vacuole (DV) was assessed post 
hPF4 treatment. Analysis of membrane potential revealed no perturbation of the 
mitochondria, however a significant loss of proton potential was observed in the DV 
within minutes of treatment (Figure 2.3). To further investigate this novel perturbation to 
the DV, transgenic parasites expressing green fluorescent protein (GFP)-tagged 
plasmepsin-II in the DV [85] were treated with hPF4 and followed by fluorescence 
microscopy over a 10-minute time course. Parasites were assayed for both hPF4 
localization using immunofluorescence analysis (IFA) and direct GFP signal (integrity of 
the DV; Figure 2.4). Within 1 minute of hPF4 incubation, hPF4 staining could be 
detected in the cytoplasm of only infected erythrocytes. hPF4 continued to accumulate 
over the next several minutes, wherein it entered the parasite cytoplasm and colocalized 
with the parasite DV. Next, severe perturbation of the DV allowed GFP to diffuse 
throughout the parasite cytoplasm (Figures 2.4,8,9). Western blot analysis of hPF4 
confirmed the IFA results showing entry into erythrocytes by 1 minute followed by 
accumulation into the parasite within 5 minutes (Figure 2.5). To assess the loss of DV 
integrity on the population level, we utilized quantitative flow cytometry to first capture 
images of individual parasite-infected cells, then quantitatively differentiate based on DV 
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Figure 2.3: hPF4 causes loss of membrane potential of the DV. Parasite-infected erythrocytes pre-
incubated with rhodamine 123 (1 µM for parasite plasma membrane potential; 0.2 µM for mitochondrial 
potential) or 10 nM LysoTracker Red and then treated over a 4-hr time course with 10 µM hPF4 or a 10 
µM mixture of ionophores Monensin and Nigericin (Mon/Nig). Length bar is 10 µm in each figure. 
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Figure 2.4: hPF4 causes lysis of the DV. hPF4 accumulates in the infected erythrocyte cytoplasm prior 
to lysis of the DV by immunofluorescence. Erythrocytes infected with parasites expressing plasmepsin-II-
GFP (PM-II-GFP) were treated with 1 µM hPF4 over a 10 min time course. Within 1 minute of PF4 
incubation, PF4 staining is seen in the cytoplasm of infected erythrocytes until entering and inducing 
lysis of the parasite DV, as shown by GFP signal diffusion through the entire parasite cytoplasm. (Green: 
PM-II-GFP [DV]; red: hPF4 IFA; blue: parasite nuclei.) 
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Figure 2.5: Western blot analysis of hPF4 accumulation in infected erythrocytes. Western blot 
analysis of erythrocyte fractions or parasite lysates shows early accumulation of hPF4 in infected 
erythrocytes, followed by persistence in the parasite. 
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Figure 2.6: Quantitative analysis of DV lysis by hPF4. ImageStream flow cytometry shows a dose-
dependent increase in PM-II-GFP parasites with a fluorescence surface area of >2 µm2, an indication of 
DV lysis, upon treatment with hPF4. Intact DVs have fluorescent surface areas <0.2 µm2. Data shown 
are means ± SEM. (*p<0.05, **p<0.01) 
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Figure 2.7: Transmission Electron Microscopy images of DV lysis by hPF4. TEM images reveal 
dissolution of the DV membrane upon treatment with 10 µM PF4, as well as dispersal of hemozoin 
fragments throughout the cytoplasm (red arrowheads). Mock-treated controls showed complete integrity 
of the DV membrane (white arrowheads), encapsulating all hemozoin crystals. (N: parasite nucleus). 
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Figure 2.8: Texas Red Dextran imaging of trophozoite DV lysis by hPF4. Trophozoite-infected 
Texas Red Dextran-loaded erythrocytes show dispersal of fluorescence into the parasite cytoplasm 
(indicating DV lysis) following 5 min of treatment with hPF4. 
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Figure 2.9: Texas Red Dextran imaging of gametocyte DV lysis by hPF4. Gametocyte-infected 
Texas Red Dextran-loaded cells show dispersal of fluorescence into the parasite cytoplasm (indicating 
DV lysis) upon 5 min of treatment with hPF4. 
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fluorescent surface area (SA) intact DVs (<0.2 µm2) from lysed DVs (>2 µm2; Figure 2.6, 
Figure 2.10). hPF4 treatment caused dose-dependent DV lysis, with nearly complete DV 
lysis on a population level upon exposure to 10 µM hPF4. The loss of DV integrity was 
confirmed at high resolution using transmission electron microscopy imaging to compare 
untreated and hPF4-treated parasites, revealing the complete loss of DV integrity in the 
hPF4-treated parasites versus mock-treated parasites with a clearly delineated DV 
membrane (white arrowheads; Figure 2.7). In addition to the loss of DV organellar 
structure, hemozoin crystals were seen dispersed throughout the parasite (red 
arrowheads). Thus, DV lysis appears to be the primary and novel mechanism of hPF4 
action against parasites. Parasite stages that rely heavily on DV function were especially 
susceptible to hPF4 treatment (Figure 2.11). 
The HDP-like C-terminus of hPF4 has antiparasitic activity 
hPF4 is comprised of three domains: an N-terminal chemokine domain, a central domain 
responsible for homotetramerization, and a C-terminal amphipathic helical region with 
HDP activity [46]. To test the hypothesis that the HDP-like C-terminus has activity 
against the malaria parasite, the 12-residue domain (C12, Figure 2.12A) was 
synthesized and tested against P. falciparum in vitro (Figure 2.12B). C12 acted similarly 
to the parental protein causing loss of parasite DV integrity, was not hemolytic, and did 
not perturb the PPM or mitochondrial membrane potential after a 4-hour treatment 
(Figure 2.13). Treatment of PM-II-GFP parasites with 100 µM C12 led to leakage of GFP 
into the parasite cytoplasm following 30 minutes of exposure, indicating loss of DV 
integrity (Figures 2.14,15). In order to ascertain localization of C12 upon treatment, 
Figure 2.16 shows that a fluorescently-tagged C12 peptide, C12-TAMRA, entered only 
infected erythrocytes within 15 minutes of treatment, with accumulation in the parasite 
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Figure 2.10: Representative flow plots from mock-treated parasites expressing PM-II-GFP or 
parasites treated with 1 µM hPF4, 3 µM hPF4, or 10 µM hPF4. Synchronous PM-II-GFP parasites 
were used to examine DV integrity upon treatment. DV lysis is defined as area of GFP signal greater 
than 2 µm2 (red line is minimum area), as GFP signal would disperse into the entire parasite cytoplasm. 
Intact DVs show compact area (less than 0.2 µm2; blue line is maximum area). 
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Figure 2.11 
Figure 2.11: Parasite stages that rely on DV function are more susceptible to hPF4 killing. Stage-
specific killing of PF4 shows increased efficacy during the stages that rely heavily on DV function (late 
ring, trophozoite, schizont, gametocyte). Shown are means ± SEM; n=3.  
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Figure 2.12 
Figure 2.12: The C-terminal amphipathic helical domain of PF4 retains the HDP activity against P. 
falciparum. (A) Projected helical wheel of C12 with each amino acid numbered. (B) Peptide derivatives 
of the PF4 C-terminal domain with lysine residues mutated to alanines to determine the necessity of 
positive charges for C12 antimalarial activity. Mutated residues are denoted by “A” followed by the 
residue number. IC50s are means ± SEM (n=3). (C) Dose-response curves for PF4, C12, and the series 
of C12 lysine mutants. Data shown are means ± SEM. 
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Figure 2.13: C12 causes loss of membrane potential of the DV. Parasite plasma membrane, 
mitochondrial, and DV potential were examined upon C12 treatment. Parasite-infected erythrocytes pre-
incubated with rhodamine 123 (1 µM for parasite plasma membrane potential; 0.2 µM for mitochondrial 
potential) or 10 nM LysoTracker Red and then treated over a 4-hr time course with 100 µM C12 or a 10 
µM mixture of ionophores Monensin and Nigericin (Mon/Nig). Length bar is 10 µm in each figure. 
29	  
	  
 
 
 
GFP/DAPIDV GFP
MERGE
DIC
0
30
60
Time (min)
15
!"#$%&'()*+Figure 2.14 
Figure 2.14: C12 causes DV lysis. C12-treated PM-II-GFP parasites showed loss of DV integrity. 
Green: PM-II-GFP (DV); blue: parasite nuclei. 
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Figure 2.15 
Figure 2.15: Texas Red Dextran imaging of trophozoite DV lysis by C12. Trophozoite-infected Texas 
Red Dextran-loaded erythrocytes show dispersal of fluorescence into the parasite cytoplasm (indicating 
DV lysis) following 30 min of treatment with 100 µM C12.  
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Figure 2.16: Imaging of fluorescent-tagged C12. C12-TAMRA treatment of PM-II-GFP parasites 
shows accumulation within infected erythrocytes and parasite bodies within 15 minutes of exposure, 
followed by DV lysis within 60 minutes of treatment. Red: C12-TAMRA; green: PM-II-GFP (DV); blue: 
parasite nuclei. 
32	  
	  
body and the erythrocyte cytoplasm while the DV remained intact. Within 60 minutes of 
treatment, GFP signal permeated throughout the parasite body, indicating lysis of the 
DV. As the cationic amphipathicity of HDPs is thought to be key to their mechanism of 
action, we reasoned that lowering the number of charges on C12 would adversely affect 
its activity. Starting at the N-terminus, mutation of the first or the first two of the four 
lysines caused only a minor decrease in activity (IC50 values of 84.0 µM and 92.1 µM, 
respectively), while mutation of the first three lysines ablated the antiparasitic activity of 
C12 (IC50 of > 200 µM; Figure 2.12B,C). The quadruple mutant was not tested due to its 
insolubility. These data suggest that, like most HDPs, activity of the amphipathic C12 
peptide is dependent on a minimal cationic charge density. 
Synthetic small molecule HDP mimics are potent against P. falciparum and have a 
mechanism similar to hPF4 
Given their broad activity, HDPs appear to be ideal therapeutic agents, though 
significant pharmaceutical issues have severely hampered clinical progress, including 
poor tissue distribution, systemic toxicity, and difficulty and expense of manufacturing 
[86]. In addition, PF4 has been reported to worsen experimental cerebral pathology in 
mice, presumably mediated through the chemokine domain [62]. Thus, we reasoned that 
synthetic small molecules capable of adopting amphipathic secondary structures 
analogous to a HDP could potentially reproduce the potent, selective antiparasitic 
activity of PF4, while improving tissue distribution and decreasing complications arising 
from chemokine signaling. In addition, these small molecule HDP mimics (smHDPs) are 
significantly less expensive to produce (an example scaffold is shown in Figure 2.17). In 
order to exploit the DV lysis mechanism of PF4 in a drug discovery effort, a library of 
~1000 nonpeptidic smHDPs [27, 87] was tested against P. falciparum. 132 compounds
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Figure 2.17: Conceptual design of smHDPs from HDPs. Top: Amphipathic structure of magainin 2; 
cationic groups in blue, nonpolar groups in green, peptide backbone in yellow. Bottom: de novo designed 
smHDPs capture the facially amphipathic architecture and critical physicochemical properties needed to 
establish robust antimicrobial activity. 
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were determined to be initial “hits” (14.3% hit rate), using a cutoff of 80% parasite death 
at 500 nM (Z’ = 0.720; Figure 2.18). 74 compounds were selected for follow-up IC50 
determination (PMX004-1120, Table 2.3). Based on these hits, additional compounds 
were synthesized (PMX1154-1422, Table 2.3) and 7 structurally diverse compounds 
were chosen as “leads” based on high potency against P. falciparum, low hemolytic 
potential (Table 2.4), and low mammalian cell cytotoxicity. These lead compounds also 
showed similar potency across a panel of chloroquine-sensitive (3D7, HB3) and 
chloroquine-resistant (Dd2, 7G8, K1) parasite lines (Table 2.1). Several of the lead 
compounds displayed little activity against Gram-positive and Gram-negative bacteria, 
and mammalian cells, indicating that a high level of specificity can be built into these 
nonpeptidic scaffolds. Secondarily, specificity can also be found between simple single 
cell eukaryotic pathogens and mammalian cells (Table 2.2). Although all lead 
compounds showed a similar mechanism of action as PF4, based on acute animal 
tolerability studies, PMX1207 and PMX207 were selected for more rigorous mechanistic 
analysis (structures shown in Figure 2.19). 
Treatment of P. falciparum parasites with either PMX1207 or PMX207 disrupted 
DV membrane potential within 15 minutes of treatment but did not disturb the PPM or 
mitochondrial potential, even after 4-hour treatment (Figure 2.20). In addition, treatment 
of the transgenic PM-II-GFP parasites with PMX1207 and PMX207 resulted in rapid 
diffusion of GFP through the parasite cytoplasm indicating a catastrophic loss of DV 
membrane integrity in a manner similar to that observed for hPF4 (Figure 2.21; other 5 
leads shown in Figure 2.22). Quantitative flow cytometry analysis indicated a dose- 
dependent effect on DV lysis, with nearly complete DV lysis within the treated population 
upon treatment with 1 µM of PMX207 or PMX1207 (Figure 2.23). We further investigated 
the intracellular localization and distribution of the smHDPs using PMX496, a potent 
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Figure 2.18 
Figure 2.18: Screen of smHDPs reveals potent inhibitors of P. falciparum growth. Screen of 920 
smHDPs at 500 nM against P. falciparum. Parasite death was normalized to a chloroquine control 
(14.3% hit rate, Z’ = 0.720). 
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Table 2.1: Screen of lead smHDPs against a panel of P. falciparum strains. Lead smHDPs were 
screened against a panel of chloroquine-sensitive and chloroquine-resistant P. falciparum lines. Chloroquine 
was used as a positive control for parasite death. IC50s are as mean ± SEM, n>3 for each compound. 
Cytotoxicity (EC50) determined against mouse 3T3 fibroblasts and human transformed liver HepG2 cells 
using an MTS viability assay. 
 
Table 2.2: Screen of smHDPs against P. falciparum and bacteria. Comparison of anti-P. falciparum (Pf; 
3D7 strain) and antibacterial activities. Bacteria strains: E. coli 25922 (EC), S. aureus 27660 (SA), E. 
faecalis 29212 (EF), P. aeruginosa 10145 (PA), K. pneumoniae 13883 (KP). 
 
Compound
3D7
IC50 (nM)
HB3
IC50 (nM)
Dd2
IC50 (nM)
7G8
IC50 (nM)
K1
IC50 (nM)
3T3
EC50 (µM)
HepG2
EC50 (µM)
Chloroquine 8.7 ± 3.3 8.7 ± 1.0 24.6 ± 2.7 37.0 ± 5.8 47.1 ± 6.0 - -
PMX207 153 ± 13 133 ± 13 134 ± 10 104 ± 9 95 ± 13 463 536
PMX496 160 ± 60 150 ± 70 170 ± 70 160 ± 60 170 ± 70 139 80
PMX504 160 ± 60 160 ± 60 118 ± 16 113 ± 15 170 ± 70 322 356
PMX611 60 ± 20 26 ± 8 49 ± 14 66 ± 14 57 ± 10 769 830
PMX647 160 ± 60 170 ± 70 300 ± 100 300 ± 100 610 ± 66 284 433
PMX835 220 ± 50 200 ± 70 300 ± 100 200 ± 70 200 ± 70 >1000 >1000
PMX1207 110 ± 12 104 ± 20 75 ± 11 91 ± 7 83 ± 4 65.1 165
CQ-sensitive P. falciparum CQ-resistant P. falciparum Mammalian Cells
!"#$%&'()
Compound
Pf  IC50 
(µg/mL)
Ec MIC 
(µg/mL)
Sa MIC 
(µg/mL)
Ef MIC 
(µg/mL)
Pa MIC 
(µg/mL)
Kp MIC 
(µg/mL)
PMX207 0.17 >50 >50 50 >50 >50
PMX496 0.093 50 50 50 >50 >50
PMX504 0.12 >50 12.5 25 >50 >50
PMX611 0.032 >50 12.5 25 >50 >50
PMX647 0.14 >50 50 25 >50 >50
PMX835 0.20 25 12.5 25 >50 50
PMX1207 0.089 0.78 0.78 0.78 6.25 12.5
!"#$%&'('
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Table 2.3: IC50 values of smHDP hits. IC50 values determined in 3D7 (CQ-sensitive) and Dd2 (CQ-
resistant) P. falciparum for 74 hits from smHDP screen and derivative compounds not included in original 
screen. Parasites were treated in triplicate, n = 2. 
Compound 3D7 IC50 
(nM) 
Dd2 IC50 
(nM) 
Compound 3D7 IC50 
(nM) 
Dd2 IC50 
(nM) 
Chloroquine 8.7 24.6 614 864 966 
Artesunate 19.4 12.1 616 149 97 
004 563 740 617 110 172 
015 438 601 633 272 457 
018 668 611 647 160 300 
033 306 419 651 148 267 
048 295 484 661 175 200 
053 740 1154 730 1150 975 
056 653 993 731 1164 964 
058 1233 1219 734 610 980 
062 413 426 781 147 207 
073 204 274 800 610 431 
092 1024 713 819 724 951 
112 688 740 832 358 368 
143 870 688 835 220 300 
146 322 244 847 870 1076 
152 221 170 848 625 709 
158 683 827 868 881 886 
160 151 168 893 200 301 
192 1198 1010 1007 1283 2747 
201 125 85 1011 880 795 
207 153 134 1012 656 555 
217 569 591 1032 1197 798 
224 893 524 1045 706 398 
235 146 108 1064 1098 1132 
256 1064 344 1065 680 664 
270 732 803 1068 644 682 
459 1365 1632 1070 650 724 
462 1283 2120 1076 N/A N/A 
474 991 1226 1086 812 1054 
484 655 1095 1088 734 602 
485 841 1006 1095 1141 786 
493 904 1183 1096 58 90 
496 160 170 1099 1163 667 
501 593 393 1101 672 656 
504 160 118 1107 1102 997 
610 N/A N/A 1115 696 829 
611 60 49 1120 308 331 
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Compound 3D7 IC50 
(nM) 
Dd2 IC50 
(nM) 
Compound 3D7 IC50 
(nM) 
Dd2 IC50 
(nM) 
1154 530 N/T 1284 160 135 
1158 563 N/T 1287 2819 N/T 
1159 493 N/T 1301 226 N/T 
1164 N/A N/T 1302 160 132  
1165 161 N/T 1305 N/A N/T 
1170 81 N/T 1306 1299 N/T 
1179 1125 N/T 1307 1256 N/T 
1185 15.5 N/T 1308 629 N/T 
1199 2932 N/T 1310 2203 N/T 
1200 2681 N/T 1324 602 N/T 
1201 3376 N/T 1325 112 N/T 
1206 3284 N/T 1338 N/A N/T 
1207 110 75 1364 N/A N/T 
1209 1503 N/T 1374 641 N/T 
1210 658 N/T 1375 88.3 N/T 
1211 976 N/T 1382 126 N/T 
1213 N/A N/T 1387 N/A N/T 
1219 3050 N/T 1398 131 N/T 
1220 N/A N/T 1399 N/A N/T 
1221 N/A N/T 1400 473 N/T 
1222 3603 N/T 1403 116 N/T 
1223 3079 N/T 1407 795 N/T 
1224 297 N/T 1408 77.1 N/T 
1226 2523 N/T 1410 N/A N/T 
1229 202 N/T 1411 N/A N/T 
1237 255 N/T 1412 N/A N/T 
1249 1716 N/T 1413 N/A N/T 
1258 247 N/T 1414 N/A N/T 
1260 N/A N/T 1415 N/A N/T 
1267 N/A N/T 1416 N/A N/T 
1268 3480 N/T 1417 N/A N/T 
1269 3029 N/T 1418 187 N/T 
1271 2318 N/T 1422 738 N/T 
1283 2445 N/T    
N/A = Not Active 
N/T = Not Tested 
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Table 2.4: Percent hemolysis of 15 smHDPs, PF4, and melittin. Hemolytic activity was determined for 15 
smHDPs (2.5 µM), melittin (15 µM), hPF4 (15 µM), chloroquine (250 nM), and artesunate (250 nM). Parasite 
cultures were treated in triplicate, n = 3. 
Compound %Hemolysis (± SD) 
Untreated 0.19% ± 0.28% 
Chloroquine 0.01% ± 0.03% 
Artesunate 0.18% ± 0.13% 
Melittin 87.3% ± 18.5% 
PF4 2.08% ± 0.78% 
207 0.00% ± 0.00% 
1096 0.09% ± 0.16% 
647 0.16% ± 0.15% 
160 0.22% ± 0.12% 
235 0.00% ± 0.00% 
201 0.00% ± 0.00% 
152 0.00% ± 0.00% 
496 0.42% ± 0.62% 
504 0.19% ± 0.25% 
611 0.00% ± 0.00% 
661 0.35% ± 0.60% 
835 0.15% ± 0.24% 
616 0.12% ± 0.09% 
617 0.30% ± 0.32% 
1207 0.14% ± 0.06% 
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Figure 2.19: Chemical structures of PMX207 and PMX1207. 
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Figure 2.20 
Figure 2.20: smHDP treatment causes loss of membrane potential of the DV. Parasite plasma 
membrane and mitochondrial potential was examined during treatment with PMX207 or PMX1207, with 
no discernible loss of fluorescence, unlike the positive controls. Compromise of DV integrity was 
monitored with LysoTracker Red, wherein loss of DV fluorescence was seen within 15 min of smHDP 
treatment, though no loss of parasite plasma membrane potential occurs. 
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Figure 2.21: smHDP treatment causes DV lysis. Loss of DV integrity upon smHDP treatment of PM-II-
GFP P. falciparum parasites. Green: PM-II-GFP (DV); blue: parasite nuclei. 
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Figure 2.22 
Figure 2.22: DV lysis imaging of 5 other smHDP leads. Visualization of DV lysis by smHDPs by 
fluorescence microscopy. PM-II-GFP P. falciparum parasites were treated with compounds PMX504, 
PMX611, PMX647, PMX835, PMX496, or PMX1269 (250 nM) over a 5-min time course and imaged via 
fluorescent microscopy. In untreated parasites, the GFP signal is an isolated structure, indicating an 
intact DV. The GFP signal after smHDP treatment spans the entire parasite body, indicating loss of 
digestive vacuole integrity. The uncharged analogue of PMX496, PMX1269, did not cause DV lysis. 
Green: PM-II-GFP (DV); blue: parasite nuclei. 
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smHDP with intrinsic fluorescence. PMX496 appeared to accumulate in the parasite 
body within 30 seconds, then concentrated in the DV at 1 minute, prior to dissipation 
throughout the parasite body, indicating a loss of DV membrane integrity (Figure 2.24). 
Since cationic amphipathicity is predicted to be necessary for smHDP antiparasitic 
action, an uncharged isosteric analog of PMX496 was synthesized (PMX1269, IC50 > 
2.5 µM; structures in Figure 2.25). As expected, treatment with the uncharged analog did 
not result in DV lysis, as with the triple alanine C12 mutant. High-resolution transmission 
electron microscopy and 3D tomograms revealed a complete loss of integrity of the DV 
after treatment with either PMX1207 or PMX207 (Figure 2.26). In addition to free 
hemozoin crystals (red arrowheads), images showed an accumulation of undigested 
hemoglobin-containing vesicles (yellow arrowheads; Figures 2.26,27). Mock-treated 
parasites showed clear delineating DV membranes (white arrowheads). DV lysis and 
killing was also evident in Texas Red Dextran-loaded erythrocytes infected with either 
trophozoite-stage parasites (Figure 2.28) or gametocytes (Figure 2.29). Loss of 
gametocyte DV integrity would likely result in parasite death and indicates that smHDPs 
may have transmission-blocking potential. To further assess the antimalarial capacity of 
PMX207 and PMX1207, they were screened against an additional 5 P. falciparum 
isolates encompassing a diverse set of malaria endemic regions and antimalarial drug 
resistance characteristics (Table 2.5). All lines were comparably susceptible to these 
smHDPs, reiterating their potential as antimalarials.  
HDP and smHDP activity reduce parasitemia in a murine malaria model 
We next tested PF4 and its HDP domain C12 in a non-experimental cerebral malaria 
(non-ECM, P. yoelii 17XNL) murine malaria model using the 4-day Peters suppression 
test [88]. mPF4 treatment significantly reduced parasitemia by 4-fold, while the HDP 
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Figure 2.23: Quantitative analysis of DV lysis by smHDPs. ImageStream flow cytometry shows a 
dose-dependent increase in PM-II-GFP parasites showing a fluorescence surface area of >2 µm2, an 
indication of DV lysis, upon treatment with PMX207 or PMX1207. Intact DVs have fluorescent surface 
areas <0.2 µm2. Data shown are means ± SEM. (*p<0.05, **p<0.01). 
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Figure 2.24 
Figure 2.24: DV lysis imaging of the intrinsically fluorescent smHDP PMX496. Fluorescent 
microscopy of the intrinsically fluorescent PMX496 shows accumulation within the parasite cytoplasm 
and DV prior to DV lysis.  
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Figure 2.25 
Figure 2.25: Chemical structures of PMX496 and its inactive analogue PMX1269.  
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Figure 2.26: Transmission Electron Microscopy images of DV lysis by smHDPs. TEM images 
reveal complete dissolution of the DV membrane upon PMX207 or PMX1207 treatment, with dispersal of 
hemozoin crystals (red arrowheads) throughout the cytoplasm and an accumulation of undigested 
hemoglobin-containing vesicles (yellow arrowheads). Mock-treated parasites retained a clear delineating 
DV membrane (white arrowheads), encapsulating all hemozoin crystals. (N: parasite nucleus). 
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Figure 2.27: Quantification of hemoglobin-containing vesicles. Number of hemoglobin-containing 
vesicles in electron micrographs of parasites treated with 10 µM hPF4, 500 nM PMX207, or 500nM 
PMX1207 was counted and compared to mock (DMSO)-treated controls.  Data shown is mean ± 
standard deviation of 50 parasites (*p<0.05). 
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Figure 2.28: Texas Red Dextran imaging of trophozoite DV lysis by PMX1207. Visualization of DV 
lysis by PMX1207 with Texas Red Dextran-loaded erythrocytes. Trophozoite-infected Texas Red 
Dextran-loaded cells show dispersal of fluorescence into the parasite cytoplasm following treatment with 
PMX1207, indicating loss of DV integrity. 
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Figure 2.29: Texas Red Dextran imaging of gametocyte DV lysis by PMX1207. Visualization of DV 
lysis by PMX1207 with Texas Red Dextran-loaded erythrocytes. Gametocyte-infected Texas Red 
Dextran-loaded cells show dispersal of fluorescence into the parasite cytoplasm following treatment with 
PMX1207, indicating loss of DV integrity. 
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Table 2.5: IC50 values for PMX207 and PMX1207 in an expanded panel of P. falciparum strains. IC50 
values are reported as means. Parasite cultures were treated in triplicate, n = 2. 
P. falciparum 
strain 
Chloroquine IC50 
(nM) 
PMX207 IC50 
(nM) 
PMX1207 IC50 
(nM) 
3D7 8.7 153 110 
HB3 8.7 133 104 
Dd2 24.6 134 75 
7G8 37.0 104 91 
K1 47.1 95 83 
T2/C6 4.2 60 69 
V1/S 74.4 165 65 
Indo 41.8 190 134 
NF54;E 8 117 110 
MT/S1 6.7 157 73 
 
domain C12 reduced parasitemia by 3-fold (Figure 2.30A,B), indicating that the HDP 
domain retained antimalarial activity during disease stages in vivo, aside from cerebral 
malaria. In an ECM model (P. berghei ANKA), C12 reduced parasitemia compared to 
controls on day 5, however, by day 7 (3 days after cease of treatment), parasitemia in 
the C12 treated mice were significantly higher than controls (Figure 2.30C). This data 
suggests that even the C12 domain of PF4 has some immunomodulatory activity that 
has a negative impact on survival in the P. berghei ANKA model of cerebral malaria; 
therefore, we felt that that the smHDPs have the best potential as antimalarials. 
In order to further explore the antimalarial properties of lead smHDPs, PMX207 
and PMX1207 were assessed for their ability to limit parasite growth in vivo in both a 
non-ECM and ECM murine malaria model. PMX207 and PMX1207 antiparasitic activity 
was assessed using the 4-day Peters suppression test against P. yoelii 17XNL and P. 
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Figure 2.30 
Figure 2.30: hPF4 and C12 reduce parasitemia in a mouse malaria model. (A) Mice infected with P. 
yoelii 17XNL show decreased parasitemia on day 4 when treated with 10 mg/kg mPF4 (n=3) compared 
to controls (n=5, p < 0.001). Shown are mean parasitemias ± SEM. (B) Mice infected with P. yoelii 
17XNL show decreased parasitemia on day 4 when treated with C12 (n=4) compared to controls (n=5, p 
< 0.001). Shown are mean parasitemias ± SEM. (C) Mice infected with P. berghei ANKA showed a 
significant decrease in parasitemia upon treatment with 10 mg/kg C12 (n=5) compared to controls (n=5) 
on day 5 (p < 0.001). However, by day 7, C12-treated mice had significantly higher parasitemias than 
controls (p < 0.05). Shown are mean parasitemias ± SEM. 
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Figure 2.31 
Figure 2.31: smHDP leads decrease parasitemia in a mouse malaria model. (A) Parasitemias of 
Swiss Webster mice infected with P. yoelii 17XNL parasitized erythrocytes via i.v. injection and treated 
with vehicle (n=5); 5 mg/kg PMX1207 (n=7); or 20 mg/kg of PMX207 (n=5). Parasitemia was assessed 
on days 4 and 6. Shown are the means ± SEM. (*p<0.05; ***p<0.001) (B) Parasitemias of C57Bl/6 mice 
infected with P. berghei ANKA parasitized erythrocytes via i.v. injection and treated with vehicle (n=10); 5 
mg/kg PMX1207 (n=5); or 20 mg/kg of PMX207 (n=5). Parasitemia was assessed on days 5 and 7. 
Shown are the means ± SEM. (*p<0.05; ***p<0.001). (C) Survival curves for P. berghei ANKA infected 
mice. p = 0.14 in the log-rank Mantel-Cox test. 
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berghei ANKA (Figure 2.31A,B). PMX207 completely eliminated parasitemia in both 
models on days 4 and 5 while PMX1207 showed a significant decrease in parasite 
growth, suppressing parasitemia at least 5-fold over vehicle-treated controls. Both 
compounds also increased mouse survival in the ECM model (Figure 2.31C), with all 
PMX207 mice surviving through day 20. These data provide in vivo validation that 
smHDP compounds show promise as a new class of antimalarials. 
2.3 Discussion 
In this work we show that the human HDP protein, PF4, and its HDP domain alone (C12) 
kill Plasmodium parasites by lysing the parasite DV. Moreover, we screened a library of 
smHDPs and found molecules that preserved this mechanism of parasite killing while 
increasing potency (Figure 2.32). Thus, targeting the lysosome-like vesicles of protozoan 
parasites may be an evolutionarily selected mechanism for mammalian hosts to kill 
Plasmodium, and is a mechanism that may be exploited for drug discovery. How 
proteins such as PF4, just the C12 HDP domain of PF4, or smHDPs enter host cells is 
still an open question and beyond the scope of this work. However, we provide evidence 
these molecules enter only infected erythrocytes and that this entry process can be 
blocked by pre-incubating with protamine sulfate, a cationic peptide that can also bind to 
heparin (Figure 2.33). This indicates the importance of initial electrostatic interactions 
with the infected host cell membrane or membrane proteins. Since only infected cells are 
targeted, and parasite viability is important for uptake, this suggests that a parasite-
derived or activated endocytosis-like mechanism could allow for large molecules such as 
PF4 or C12 to enter, while channels/pores or passive diffusion could be responsible for 
smHDP uptake. 
In closing, human PF4 has the ability to kill blood stage parasites in vitro, and its 
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Figure 2.32 
Figure 2.32: Proposed PF4 and smHDP mechanism of action. PF4/smHDPs enter the host 
erythrocyte via an unknown mechanism. The PF4 or smHDPs are then taken up through the cytostome 
with the host cell cytoplasm, packaged into vesicles, and then sent to the digestive vacuole for 
hemoglobin digestion. Upon reaching a critical concentration, the PF4/smHDPs insert into the digestive 
vacuole membrane, causing disruptions and lysis. This ultimately results in parasite death. N = nucleus. 
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Figure 2.33 
Figure 2.33: hPF4 causes dose-dependent DV lysis limited by protamine sulfate. PM-II-GFP 
parasite-infected erythrocytes were pretreated with 5 mM protamine sulfate or mock (DMSO) for 30 
minutes, then treated with 10 µM hPF4 for 10 minutes prior to fixation and permeabilization.  hPF4 
immunofluorescence (red) shows no appreciable signal in the protamine sulfate pretreated erythrocytes, 
while mock-pretreated erythrocytes show hPF4 accumulation within the erythrocyte. Red: hPF4 IFA; 
green: PM-II-GFP (DV); blue: parasite nuclei. 
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low hemolytic potential and selective targeting of the parasite DV endow it with 
properties that are well tolerated in the bloodstream. However, it is unlikely that PF4 
would make a useful therapeutic for malaria treatment due to the cost of goods and 
potential of increased inflammatory damage during cerebral malaria. Thus, we believe 
the development of smHDPs may overcome these issues while preserving this unique 
mechanism of action; thus smHDPs represent a new class of small molecules with 
effective therapeutic potential for combating this human disease where efforts are 
currently challenged with rampant drug resistance. 
2.4 Experimental Procedures 
Parasite culture and IC50 determination 
P. falciparum parasites were cultured according to standard conditions [89] with minor 
modifications. Parasites were maintained in fresh human erythrocytes suspended at 4% 
hematocrit in RPMI 1640 supplemented with 0.5% Albumax II, 0.2% NaHCO3, 50 µg/L 
hypoxanthine and 50 µg/l gentamicin and incubated at 37°C under a gas mixture of 5% 
O2, 5% CO2 and 90% N2. For IC50 determinations, compounds were assayed for 72h, 
after which the cultures were fixed with a solution of 4% paraformaldehyde and 0.008% 
glutaraldehyde in PBS prior to permeabilization with 0.25% Triton X-100, and 5 µM 
SYTOX Green Nucleic Acid Stain and flow cytometry analysis (Accuri C6 Flow 
Cytometer with C-Sampler). IC50 curves were generated using GraphPad Prism. 
HDP screen and assay for hemolysis.  
P. falciparum parasites (3D7 strain) were cultured as described previously. 
Synchronized parasites were treated with 15 µM of 9 platelet-, neutrophil-, or 
lymphocyte-derived proteins containing HDP-domains or properties: Regulated upon 
Activation, Normal T-cell Expressed, and Secreted (RANTES, ProSpec); Platelet Factor-
59	  
	  
4 (PF4, Haematologic Technologies Inc.); Fibrinopeptide-A (FP-A, AnaSpec); 
Fibrinopeptide-B (FP-B, AnaSpec); Human Neutrophil Peptide-1 (HNP-1, AnaSpec); 
Human Neutrophil Peptide-2 (HNP-2, AnaSpec); Cathelicidin (LL-37, AnaSpec); 
Lymphotactin (ProSpec); Lactoferrin (ProSpec). 15 µM melittin, the major active 
component of bee venom, was used as a positive control for HDP-killing of parasites 
with complete hemolysis. Parasite death was normalized to a 500 nM artesunate control. 
Parasites were treated for 72 hours, and then fixed and assayed for parasitemia via flow 
cytometry. Hemolysis was measured by removing 50 µL from each well (100 µL total in 
a 96-well plate) before fixing and transferring to a clear-bottom plate. Absorbance at 541 
nm was measured and compared to a standard curve generated from Triton X-100-lysed 
erythrocytes (4% hematocrit serially diluted by 2). 
Platelet activation 
These studies were completed by Melanie G. Millholland at the University of 
Pennsylvania. Platelets were collected from C57BL/6 mice (WT), homozygous PF4 
knockout mice (PF4 KO), and transgenic mice overexpressing human PF4 (hPF4+) [64] 
and added to cultures either with or without pre-activation ex vivo with 5 µM AYP. 
Parasitemia was assessed via flow cytometry after 24 hours treatment. 
Parasite membrane potential assays 
These studies were completed in collaboration with Melanie G. Millholland at the 
University of Pennsylvania. Parasite-infected erythrocytes were incubated at 37°C for 30 
minutes with 1 µM rhodamine 123 (for parasite plasma membrane potential), 0.2 µM 
rhodamine 123 (for parasite mitochondrial potential) [90], or 10 nM LysoTracker Red (for 
digestive vacuole potential). After pre-incubation, parasites were treated for 4 hours with 
the test compound, a 10 µM mixture of the ionophores monensin (Sigma) and nigericin 
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(Calbiochem) as a positive control of membrane potential perturbation, or left untreated 
and then analyzed via fluorescence microscopy on a Leica DMI6000 B. 
Fluorescence microscopy and quantification of digestive vacuole lysis  
These studies were completed by Melanie G. Millholland at the University of 
Pennsylvania. Erythrocytes infected with synchronous cultures of PM-II-GFP expressing 
parasites were treated at 30 hours post invasion (hpi) and fixed at the indicated time 
points, stained with Hoechst and imaged by fluorescence microscopy. Cells were also 
analyzed on an Amnis ImageStream X high-resolution flow cytometer with gating for 
Hoechst-positive cells to isolate infected cells [91, 92].  
PF4 immunofluorescence 
These studies were completed by Melanie G. Millholland at the University of 
Pennsylvania. Erythrocytes infected with PM-II-GFP parasites were treated with 1 µM 
recombinant hPF4, fixed at specified time points, permeabilized with 0.1% Triton X-100 
for 10 min and assayed for PF4 immunofluorescence with hPF4 primary antibody and an 
Alexa-568 conjugated anti-rabbit secondary antibody. Parasites were imaged via 
fluorescence microscopy. 
Western blot analysis of PF4 accumulation 
These studies were completed by Melanie G. Millholland at the University of 
Pennsylvania. Synchronous cultures of P. falciparum-infected erythrocytes were treated 
with 10 µM PF4 then 0.1% saponin to separate erythrocyte fractions from parasite 
material. Samples were run by standard SDS-PAGE, transferred to Immobilon Transfer 
PVDF membrane and incubated with 1:1000 primary antibody to human PF4 and 
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1:10000 anti-mouse secondary antibody. Input of total cell lysates was used as a loading 
control, using a primary antibody to flotillin and an anti-rabbit secondary antibody. 
Peptide synthesis 
Peptides were synthesized via the solid phase method at 0.092 mmol scales using 
Fmoc-CLEARTM Amide resin (Peptides International, substitution level 0.46 mmol/g). 
Activation of Fmoc-amino acids (5-fold excess) was achieved with (2-(6-Chloro-1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate) in the presence of 
2-(N,N'-diisopropylamino) ethanol. The reaction solvent contains 100% N,N-
Dimethylformamide (HPLC grade, Aldrich). Coupling, cleavage, and precipitation 
reagents were purchased from Sigma-Aldrich. Amino acids were purchased from Chem-
Impex International Inc. Side chain deprotection and simultaneous cleavage from the 
resin were carried out using a mixture of trifluoroacetic acid/H2O/Triisoproplysilane 
(46.5:2.5:1, v/v) at room temperature, for 3 hours. Crude peptide was obtained by ether 
precipitation and purified by reverse-phase chromatography. The mass of all peptides 
was verified by ESI-MS (Agilent MSD G1956B). Analytical and preparative HPLC was 
performed using a C18 reverse-phase column on an Agilent 1200 series system (Agilent 
Technologies), with Hewlett Packard Chemstation software. 
smHDP screen  
Synchronized parasites were treated with 500 nM of each smHDP for 72 hours. Cells 
were then fixed and assayed for parasitemia via flow cytometry. Compounds were 
deemed hits if they caused ≥80% parasite death, as compared to a 500 nM chloroquine-
treated positive control. The Z-factor was calculated using the equation  
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where µ represents the means and σ represents the standard deviations of the positive 
(p) or negative (n) controls [93]. 
smHDP testing in multiple parasite, bacterial, and mammalian cell lines  
Synchronized parasite cultures: 3D7, NF54;E, Dd2, 7G8, K1, HB3, T2/C6, INDO, V1/S, 
MT/s1 (MR4, ATCC) were treated with top smHDP hits for IC50 comparison. Titrations 
for the assay were performed as described previously. Cytotoxicity (EC50) was 
determined against mouse 3T3 fibroblasts and human transformed liver HepG2 cells 
using an MTS viability assay. Bacterial cultures were grown from isolated colonies in 
Cation-Adjusted Mueller-Hinton Medium II. Compounds to be tested were prepared in 
DMSO at 10 mg/mL, diluted 1:20 in water and the added to a 96-well round-bottom plate 
in concentrations ranging from 50 µg/mL to 0.024 µg/mL following 2-fold serial dilutions 
in water. Bacteria were added at 106 cfu/mL. The cultures were incubated for 18 hours at 
37ºC. To determine inhibition, turbidity was read as ≥2mm button defined by CLSI or as 
a clear, agreeable change in the uniformity of the cultures, or defined as an 80% or 
greater reduction in pellet size compared to control wells.  
Transmission Electron Microscopy 
These studies were completed in collaboration with Melanie G. Millholland at the 
University of Pennsylvania. Synchronous cultures of P. falciparum parasites were 
magnet-purified at ~25 hpi and allowed to sit for 6 hours prior to a 10-min exposure to 10 
µM hPF4, 500 nM PMX207 or PMX1207. DMSO was used as a negative control. 
Samples were frozen in an Abra high-pressure freezer. This material was freeze 
substituted in 2% OsO4 in anhydrous acetone and embedded into Epon. Images were 
collected at 120KeV on a FEI Tecnai12 equipped with a Gatan 894 2k camera. Images 
were captured by Dewight R. Williams, Ph.D. at the Electron Microscopy Core at the 
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University of Pennsylvania. Tilt series were taken +/- 70° in 3° increments at 6500x 
magnification. Tilt images were decimated by a factor of 2 and initially aligned by cross-
correlation in FEI’s inspect3D. Tomograms were constructed from fiducially aligned 
stacks, orthogonal merged axes, and subsequent serial tomograms joined in the IMOD 
package “etomo”. Montage images taken with 10x10 sampling at 3200x magnification 
were aligned with blendmont. 
P. berghei ANKA mouse studies  
These experiments were conducted with the assistance of Satish Mishra, Ph.D. in the 
laboratory of Photini Sinnis, M.D. at the Malaria Research Institute, Bloomberg School of 
Public Health, Johns Hopkins University. C57BL/6 mice were infected with 2.5x104 P. 
berghei ANKA parasitized erythrocytes via intravenous injection. Mice were dosed once 
per day intravenously on days 1-4 with either 5 mg/kg PMX1207 (in 20% DMA in saline 
[n=5]); 20 mg/kg PMX207 (in 20% Kleptose HPB [n=5]); or untreated (Control, n=5). 
Parasitemias were determined on days 5 and 7 via Giemsa-stained blood smears. 
Statistical analyses  
We analyzed the statistical significance of DV lysis with one-tailed paired Student’s t 
tests. Mouse parasitemias were analyzed with a one-way ANOVA with Dunnett’s post-
hoc test. A Mantel-Cox log rank test was performed on the survival data, with a 
Bonferroni correction for multiple analyses. Significance was assigned to an alpha of 
0.01 for DV lysis. 
PF4 and C12 P. yoelii 17XNL mouse studies 
These experiments were conducted with the assistance of Satish Mishra, Ph.D. in the 
laboratory of Photini Sinnis, M.D. at the Malaria Research Institute, Bloomberg School of 
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Public Health, Johns Hopkins University. Swiss Webster mice were infected with 2x105 
P. yoelii 17XNL parasitized erythrocytes in 200 µL of RPMI medium via intravenous 
injection. Following a standard 4-day Peters suppression test protocol (Knight and 
Peters, 1980), the treatment regimen began on day 1 (the same day the mice were 
infected) and mice were dosed once per day intravenously on days 1-3 with vehicle 
(20% DMA in saline [n=3] or 20% Kleptose HPB [n=2]); 10 mg/kg mPF4 (in saline [n=3], 
R&D systems); or 10 mg/kg C12 (in saline [n=4]). Parasitemias were determined on day 
4 via Giemsa-stained blood smears. 
Texas Red Dextran-loaded erythrocyte analysis of DV lysis 
These studies were completed by Melanie G. Millholland at the University of 
Pennsylvania. Erythrocytes were lysed and resealed as described previously [94], in the 
presence of 10 µM Texas Red Dextran prior to challenge with synchronous magnet-
purified cultures of P. falciparum-schizont stage parasites.  Infected erythrocytes 
containing Texas Red Dextran were treated at 30 hpi with hPF4, C12, or smHDPs as 
previously described and imaged on a Leica DMI6000B epifluorescent microscope to 
assess lysis of the parasite DV, denoted by Texas Red Dextran dispersion throughout 
the parasite body.  Infected Texas Red Dextran-loaded cells were also subjected to 
gametocytogenesis as previously described [95] and treated with hPF4 or PMX1207 at 
stage 2 prior to fluorescent microscopy analysis of DV lysis. 
Protamine sulfate studies 
These studies were completed by Melanie G. Millholland at the University of 
Pennsylvania. hPF4 immunofluorescence was assayed as described previously with 
pretreatment of cultures with 5 mM protamine sulfate or mock (DMSO) for 30 min prior to 
hPF4 treatment. 
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CHAPTER 3: Structure-Function Analysis of the Antimalarial 
Activity of Platelet Factor 4 and CCL20 Chemokines 
3.1 Introduction 
Malaria continues to be a global health burden with an estimated 207 million new cases 
leading to over 600,000 deaths in 2012; most of which were in children under the age of 
5 (77%) [1]. New treatments are needed in the pipeline as resistance to the first-line 
therapy – artemisinin-based combination therapy (ACTs) – has emerged in Cambodia, 
threatening the control of Malaria worldwide [9]. Ideally, novel treatments will minimize 
resistance, though most approaches to develop therapeutics generate resistant 
parasites in the laboratory and field.  
Malaria parasites are obligate intracellular pathogens with life cycles involving 
both sexual and asexual stages of growth, where the asexual phase is thought to be the 
cause of all clinical symptoms of malaria. The asexual phase for Plasmodium sp. 
involves the intracellular infection of erythrocytes. This chronic erythrocytic stage begins 
when extracellular parasites (merozoites), initially released from the liver, invade 
erythrocytes. Over the next 48 hours, internalized parasites differentiate (ring stage), 
metabolize vast amounts of hemoglobin (trophozoite stage) in the specialized digestive 
vacuole (DV), and replicate (schizont stage) to produce expanded populations of 
invasive merozoites that are released upon rupture of the host cell [11]. Parasites must 
interact and dramatically remodel their host cell to facilitate invasion, intracellular 
development, and avoid innate/adaptive host defenses to continue this lytic cycle. 
Therapeutic agents must necessarily kill the intracellular or extracellular forms of these 
parasites to cure the disease. 
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Antimicrobial peptides (AMPs) are small (2-8 kDa) molecules that are an 
important part of innate immunity [79]. AMPs have been shown to have activity against a 
broad-range of pathogens, including bacteria, fungi, viruses, and parasites [79, 96]. 
Though they vary greatly in amino acid sequence and structure, they are united by an 
amphipathic topology that is thought to be essential to their antimicrobial activity. AMPs 
kill by interacting with pathogen membranes and causing disruptions via 
permeabilization [97]. Over 1000 AMPs have been identified to date [19], and new 
classes of proteins with antimicrobial activity continue to be discovered. 
Chemokines are small (8-12 kDa) chemotactic proteins that have roles in many 
cellular functions, including inflammation, development, angiogenesis, and immunity 
through their regulation of leukocyte cell trafficking [34-36]. There are roughly 50 human 
chemokines and 20 different transmembrane chemokine receptors have been identified 
[37]. Although they control many different functions, chemokines are remarkably 
structurally similar, consisting of an N-terminal loop necessary for receptor activation, a 
central domain comprised of 3 antiparallel β-strands that provide a stable scaffold, and a 
C-terminal α-helix that folds across the β-sheet to stabilize the overall structure (Figure 
3.1). Virtually all chemokines have four conserved cysteines (two in the N-terminal loop, 
and 2 in the β-sheet) that form two essential disulfide bonds (Cys1-Cys3 and Cys2-
Cys4). Chemokines are traditionally divided into four groups based on the positioning of 
the first two cysteines: C, CC, CXC, and CX3C, where X is any non-cysteine amino acid 
[36, 37, 41]. 
Over the past decade, many chemokines have been shown to have direct 
antimicrobial activity, in addition to their role in immunity through leukocyte recruiting [40, 
42-46]. Antimicrobial chemokines, which are expressed directly in the bloodstream, 
necessarily have low host toxicity. This is in contrast to classical AMPs, which are 
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typically expressed in phagocytes or on mucosa. Because chemokines have a highly 
conserved tertiary structure, examining the key structure-function relationships in 
antimicrobial chemokines may deconvolute their biological role in host defense, and may 
provide insights into new therapeutics against drug-resistant pathogens with minimal 
host toxicity. 
We have previously shown that CXCL4/PF4 kills P. falciparum via selective lysis 
of the digestive vacuole [98]. Because antimicrobial chemokines share such similar 
topology, we hypothesized that other chemokines may also have antimalarial activity in 
vitro. As the amphipathic α-helical C-terminal domain of chemokines is the driving 
component of antimicrobial activity, a small screen of several CC and CXC chemokine 
C-terminal domains was performed against P. falciparum parasites.  
3.2 Results and Discussion 
Considering the similarity in structure of chemokines (Figure 3.1), and because the 
amphipathic α-helix is frequently the antimicrobial fragment, we hypothesized that 
several α-helices of chemokines could have antimalarial activity. We screened 4 α-
helices from the CC and CXC groups against P. falciparum for antimalarial activity and 
hemolysis (Figure 3.2, Table 3.1). We previously determined that the helix of PF4, a 
CXC chemokine (CXCL4), was active against P. falciparum [98], and therefore included 
this peptide as a positive control. An additional CXC chemokine, CXCL8/IL8, with 
documented α-helical antimicrobial activity [99], was selected. Three CC-type 
chemokines with antimicrobial activity were also selected for the mini-screen: 
CCL5/RANTES [43], CCL13/MCP-4 [100], and CCL20/MIP-3α [76]. CCL13 helix was 
inactive, even at 250 µM, while the helices of CCL5 and IL8 showed moderate activity at 
the top concentration. All three were not hemolytic at 250 µM. Interestingly, the helix of  
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!"#$%&'()*Figure 3.1 
Figure 3.1: Chemokines have a similar tertiary structure. Seven chemokines were aligned using 
PyMOL, highlighting the similarities in the C-terminal α-helices (top), central β-sheet domains (bottom), 
as well as overall tertiary structure. CCL5 (RANTES, gray, PDB 1U4L); CCL13 (MCP-4, fuchsia, PDB 
2RA4); CCL20 (MIP-3α, green, PDB 1M8A); CXCL4 (PF4, blue, PDB 1F9Q); CXCL7 (TC-1, purple, PDB 
1BO0); CXCL8 (IL-8, yellow, PDB 1IL8); CXCL10 (IP-10, pink, PDB 1O7Z).	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Table 3.1: Antimalarial and hemolytic activity of chemokine helices. IC50 and HC50 values are 
reported as means. HC50 is defined as the concentration at which there is 50% hemolysis. PF4 helix was 
tested with a max concentration of 500µM, n = 14; CCL20 helix was tested with a max concentration of 
100µM, n = 6; all others were tested with a max concentration of 250µM n = 3. Sequences and number of 
amino acid residues are given for each peptide. Hemolysis was determined by measuring the absorbance at 
541nm in the culture media. 
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Figure 3.2 
Figure 3.2: Mini-screen of chemokine helices against P. falciparum. Helical peptides based on the 
C-terminal α-helices of five chemokines, including three CC chemokines and two CXC chemokines were 
tested against P. falciparum in vitro. All have been previously shown to have AMP activity against 
bacteria. Shown are dose-response curves for all five peptides.  
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CCL20 was potent against P. falciparum (IC50 of 6.8 µM). The hemolytic activity was 
also fairly potent, though the HC50/IC50 ratio was slightly improved compared to the 
PF4 helix (4.6 vs. 3.6, respectively). 
PF4 has confirmed antimalarial activity via direct disruption of the parasite’s 
digestive vacuole membrane [98, 101]. Because the C-terminal α-helix was necessary 
and sufficient to kill the parasites, and the full-length protein was also active (with ~14x 
increase in potency), we hypothesized that full-length CCL20 would retain antimalarial 
activity as well. CCL20 was slightly more potent than its helix (IC50 = 4.7 µM, Table 3.2), 
and surprisingly, was not hemolytic. CCL20 and its helix also killed P. falciparum via 
lysis of the DV (Figure 3.3). We next sought to explore the structure-function relationship 
of antimalarial activity and hemolysis in PF4 and CCL20 by testing a series of peptides 
based on truncations of each chemokine. We synthesized an additional 3 peptides for 
each PF4 and CCL20 based on portions of the various chemokine domains (Figure 3.4) 
via solid phase peptide synthesis (see section 3.3 Experimental Procedures). In peptides 
containing any unpaired cysteine residues, the cysteines were substituted to serine to 
prevent the formation of unwanted intra- or intermolecular disulfides that could result in 
polymerization.  
We synthesized a peptide consisting of everything but the N-terminal chemokine 
receptor-activating loop, dubbed “chemokineless” peptide. We also synthesized a “long 
peptide,” which is equivalent in length to several helical AMPs, such as melittin and 
magainin. The long peptide is comprised of the α-helix and a portion of the β-sheet 
domain to determine if even one β-strand would stabilize the helix and reduce 
hemolysis. Finally, we synthesized a peptide comprised of solely the central β-sheet 
domain. The N-terminal loop of chemokines is traditionally believed to control receptor 
activation, while the central β-sheet domain provides a stable scaffold, and the 
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Figure 3.3 
Figure 3.3: CCL20 and its helix also kill through a selective DV lysis mechanism. CCL20 (5 µM) 
and CCL20 helix (5 µM) treated PM-II-GFP parasites showed loss of DV integrity. Green: PM-II-GFP 
[DV]; blue: parasite nuclei. 
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Table 3.2: IC50 and HC50 values for PF4, CCL20 and their corresponding truncated peptide series 
against P. falciparum. Values are reported as means. The α-helix is necessary and sufficient for activity 
against the parasites. The full protein confers protection against hemolysis. 
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Figure 3.4 
Figure 3.4: Domain analysis of PF4 and CCL20. Schematic of chemokine monomer depicting each 
domain and peptide truncations. 
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amphipathic α-helix folds over the structure to add stability. However, we saw that any 
peptide lacking the N-terminal chemokine loop was less active and more hemolytic than 
the parent protein (Table 3.2). 
 To explain the differences in potency and hemolytic activity across the series of 
peptides, we examined the secondary structure character via circular dichroism 
spectroscopy (Figure 3.5, Tables 3.3,4). In the PF4 series, only the full-length protein 
retains any secondary structure in water (Figure 3.5A). The double minima at 208 nm 
and 222 nm indicate α-helical content. The secondary structure components were 
deconvoluted using CONTIN via DichroWeb (see 3.3 Experimental Procedures). In the 
CCL20 series, the full-length protein, the peptide lacking the N-terminal chemokine loop, 
and the β-sheet domain all displayed some α-helical character (Figure 3.5C). Upon 
addition of the helix-inducing trifluoroethanol (TFE, Figure 3.5B,D), all peptides showed 
helical character except for the PF4 β-sheet domain. Interestingly, the β-sheet domain of 
CCL20 was very helical with the addition of TFE (αR = 0.25 and αD = 0.21, Table 3.4). 
 Taken together with the structural data, the antimalarial activity of each series of 
peptides is dependent upon the presence of the C-terminal α-helix. Additionally, while it 
was previously believed that the α-helix folds over and provides stability to the overall 
structure of the chemokine, these data suggest that the N-terminal loop is also 
necessary to hold the structure together. Disulfide bridges are well known to confer 
stability in many types of proteins, including chemokines and chemokine receptors, and 
are often thought to be necessary for proper protein folding and function [102-104]. 
Therefore, without these disulfide bridges between the N-terminal loop and central β-
sheet domain, the peptides are unlikely to be in their native conformations and have 
expected alterations in activity and hemolysis. If the peptides are unfolded or in the 
incorrect conformation, the α-helix may be able to blindly interact with any membrane it 
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Figure 3.5 
Figure 3.5: CD analysis of PF4 and CCL20 peptide series. Circular dichroism spectra of chemokines 
and peptides derived from domain truncations of PF4 and CCL20. Full-length protein, black; 
Chemokineless (CK-), red; β-sheet domain, blue; long peptide, green; α-helix, orange. The addition of 
TFE to induce helicity is denoted by the dotted lines in each graph. PF4 and peptides in water (A) and 
50% TFE (C).  CCL20 and peptides in water (B) and 50% TFE (D).  
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Table 3.3: Secondary structure data of PF4 and CCL20 series peptides in water. Secondary structure 
data were determined experimentally from independent CD spectra of each peptide as detailed in section 
3.3 Experimental Procedures, and expressed as percent of structure for peptides in water. The indices R 
and D refer to regular and distorted structures, respectively; regular structures have a precise geometry, 
whereas distorted structures result from the finite size of the respective motifs.	  
 
Table 3.4: Secondary structure data of PF4 and CCL20 series peptides in TFE. Secondary structure 
data were determined experimentally from independent CD spectra of each peptide as detailed in section 
3.3 Experimental Procedures, and expressed as percent of structure for peptides in 50% TFE. The indices R 
and D refer to regular and distorted structures, respectively; regular structures have a precise geometry, 
whereas distorted structures result from the finite size of the respective motifs. 
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encounters, and disrupt it at high enough concentrations, relevant to the peptide’s 
potency. We therefore conclude that the entire protein must be present, in its stabilized 
and folded context, to afford protection to the host cells.  
Additionally, PF4 peptides show a great reduction in potency. This may be 
attributed to the fact that human PF4 exists naturally as a homotetramer, while human 
CCL20 is a monomer or a dimer at physiological conditions. These disulfide bridges 
between the N-terminal loop and central β-sheet domain are likely important for 
dimerization and tetramerization. Without the necessary quaternary structure, these 
peptides may not be interacting with the RBCs in the usual manner. It is believed that 
PF4 enters infected RBCs through interaction with the Duffy antigen [101], and in fact, 
conserved disulfides in the cysteine-rich Plasmodium Duffy Binding Like-domains 
(DBLs) are believed to be necessary for invasion [105]. Due to their highly conserved 
structural components, these antimicrobial chemokines may provide a unique and 
exciting scaffold from which to derive more potent antimalarial therapeutics. 
3.3 Experimental Procedures 
Parasite culture and IC50 determination  
P. falciparum parasites were cultured in RPMI 1640 (Invitrogen) supplemented with 
Albumax II (Invitrogen). For synchronization, ring stage parasites were isolated by 
treating with 5% D-sorbitol in phosphate buffered saline at 37°C for 30 minutes [106]. 
For IC50 determinations, synchronized ring-stage parasites were plated at 0.5% 
parasitemia and 8% hematocrit in 96-well plates at a total volume of 50 µL. Serial 
dilutions of 2x concentration of the respective compound were added to the wells to 
bring the total volume up to 100 µL and 4% hematocrit. Compounds were assayed for a 
72 h period, after which the cultures were fixed with a solution of 4% paraformaldehyde 
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and 0.08% glutaraldehyde in PBS. The cells were then permeabilized with 0.25% Triton 
X-100, and SYTOX Green Nucleic Acid Stain (Invitrogen) in PBS was added to a final 
concentration of 5 µM. DNA content, as an indicator of parasitemia, was analyzed on an 
Accuri C6 Flow Cytometer with C-Sampler. IC50 curves were generated using 
GraphPad Prism (GraphPad Software). 
Assay for hemolysis 
3D7 parasite-infected erythrocytes were cultured as described previously. Cultures were 
treated for 72 hours, and then assayed for hemolysis prior to fixing. Hemolysis was 
measured by removing 50 µL from each well (100 µL total in a 96-well plate) and 
transferring to a clear-bottom 96-well plate. Absorbance at 541 nm was measured and 
compared to a standard curve generated from Triton X-100-lysed erythrocytes (4% 
hematocrit serially diluted by 2). 
Peptide synthesis 
Peptides were synthesized via the solid phase method either by hand or on a CEM 
Liberty 1 Microwave Peptide Synthesizer at 0.092 mmol scales using Fmoc-Rink Amide 
resin (substitution level 0.3-0.6 meq/g; Chem-Impex International). Activation of Fmoc-
amino acids (5-fold excess) was achieved with 2-(6-Chloro-1H-benzotriazole-1-yl)-
1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU) in the presence of 2-(N,N'-
diisopropylamino) ethanol (DIPEA). The reaction solvent contains 100% N,N-
Dimethylformamide (DMF, HPLC grade; Aldrich). Coupling, cleavage, and precipitation 
reagents were purchased from Sigma-Aldrich. Amino acids were purchased from Chem-
Impex International. Side chain deprotection and simultaneous cleavage from the resin 
were carried out using a mixture of trifluoroacetic acid (TFA)/H2O/Triisoproplysilane 
(TIPS) (46.5:2.5:1, v/v) at room temperature, for 3 hours. Crude peptide was obtained by 
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ether precipitation and purified by reverse-phase chromatography. The mass of all 
peptides was verified by ESI-MS (Agilent MSD G1956B). Analytical and preparative 
HPLC was performed using a C18 reverse-phase column on an Agilent 1200 series 
system (Agilent Technologies), with Hewlett Packard Chemstation software. 
Fluorescence microscopy imaging of DV lysis 
Erythrocytes infected with synchronous cultures of PMII-GFP expressing parasites were 
treated at 30 hours post invasion (hpi) with either 5 µM CCL20 or CCL20 helix and fixed 
after 5 min of treatment, stained with Hoechst and imaged by fluorescence microscopy.  
Circular dichroism analysis 
Peptide solutions were prepared at 50µM in water, and 25µM in 50% trifluoroethanol 
(TFE). Circular dichroism studies were conducted at 25˚C on an AVIV 410 
spectropolarimeter equipped with a temperature control unit. Spectra were obtained from 
three averaged scans. Scans were conducted from 260 nm to 190 nm. Molar ellipticity 
was calculated via the formula θ = d/(l*N*c*10), where d = signal in degrees; l = path 
length (cm); N = # of amino acids; c = concentration (M). Percent α-helix, β-sheets, and 
turns were estimated using DichroWeb CONTIN [107]. 
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CHAPTER 4: Conclusions and Future Directions 
This work demonstrates an example of natural host defense against a pathogen that has 
affected humans since the dawn of man, and dissects not only how this host defense 
kills the parasite, but also translates this mechanism into a potential therapeutic. This 
natural defense is a class of proteins expressed in the bloodstream with a myriad of 
roles in homeostasis and inflammation, both through their abilities to affect cell trafficking 
and direct microbicidal activity. These proteins, called chemokines, have evolved to kill 
pathogens that they encounter without harming the host cells. This is likely due to their 
highly conserved tertiary structure, as the antimicrobial fragment alone has measurable 
toxicity to human red blood cells (RBCs), while the intact protein does not. These 
antimicrobial chemokines work through a direct membrane perturbation mechanism, 
which we demonstrate occurs specifically at the parasite digestive vacuole.  
4.1 The identification of PF4 as an antimicrobial chemokine, and its translation to 
small molecule mimics of host defense peptides 
Identification of PF4 as a natural antiparasitic 
In this work we identified the human antimicrobial protein, PF4, as an antiparasitic 
molecule that kills Plasmodium parasites by lysing the parasite DV, a vital parasite organ 
responsible for digestion of host hemoglobin. Targeting the lysosome-like vesicles of 
protozoan parasites may be an evolutionarily selected mechanism for mammalian hosts 
to kill Plasmodium and other parasites (i.e. T. brucei [108]). How proteins such as PF4 
enter host cells remains an open question, though uptake of human PF4 into the host 
erythrocyte seems to diminish following parasite DV lysis and parasite death, suggesting 
that perhaps an active, parasite-mediated mechanism allows entry of these HDP 
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molecules into the erythrocyte cytoplasm. McMorran et al. show evidence that this 
process is dependent upon PF4 interacting with the Duffy antigen on the RBC surface 
[101]. Since only infected cells are targeted, and parasite viability is important for uptake, 
this suggests that perhaps a parasite-derived or activated endocytosis-like mechanism 
could allow for large molecules such as PF4 to enter, while perhaps channels or pores 
could be responsible for small molecule uptake [109-111].  
 PF4 kills in an AMP-like fashion by targeting the DV membrane. AMPs are 
facially amphipathic, and in fact, the C-terminal peptide of PF4 requires amphipathicity 
for its antimalarial activity (Figure 2.12). Additionally, we have tested a natural variant of 
PF4, PF4var1, that has three point mutations in the C-terminus (P58L, K66E, 
L67H) [112]. This creates a net charge of +1 on the cationic face of the PF4var1 helix 
vs. the +3 charge on wild-type PF4. Interestingly, we found that both parent PF4var1 
and its C-terminal helical peptide were inactive against P. falciparum in vitro up to 10 µM 
and 500 µM, respectively (data not shown).   
Unfortunately, controlling malaria is largely dependent upon finding low cost 
therapies, as the majority of the population affected is in the developing world. The high 
cost of production of biological therapeutics make chemokines an unlikely candidate for 
a malaria drug, though harnessing their mechanism of action in the small molecule 
mimics of host defense peptides (smHDPs) may avoid these issues while preserving the 
unique mechanism of action and safety. Additionally, these small molecules are more 
chemically tractable, and therefore may more closely fit the target product profile of 
malaria drugs in the pipeline. More investigation into the specificity of these molecules 
and proteins for the digest vacuole membrane is necessary, as well as resistance 
studies, development of analogues, and in vivo studies: 
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Testing PF4 and derivatives against model liposomes based on the composition of 
parasite digestive vacuolar membranes 
To determine if PF4 selectively disrupts the DV membrane causing leakage of DV 
contents via direct membrane disruption, we will prepare model liposomes with similar 
lipid content to the parasite DV membrane and assess membrane compromise upon 
PF4 treatment. We will assess the composition of parasite DV membranes via the 
isolation of this organelle from whole parasites [113] and analysis of lipid content within 
these purified preparations via liquid chromatography-mass spectrometry (LC-MS) [114]. 
Synthetic liposomes would be prepared with the corresponding phospholipid 
composition of DV membranes, and then treated with PF4, its helix, or the synthetic 
small molecule mimics. Liposomes comprised of different phospholipids would serve as 
a control. Lysis of these DV-based liposomes would suggest that PF4 and its derivatives 
are targeting the membrane directly, and not a protein target. If there is no preference for 
the DV-based membranes, perhaps the specificity of lysing this particular organelle 
would be more dependent upon the uptake mechanism targeting these compounds to 
the DV than dependent upon the membranes themselves. 
Investigating the selective entry of PF4 and smAMPs into infected erythrocytes 
The membrane of the infected erythrocyte is vastly different than their uninfected 
counterparts. The maturation of the malaria parasite causes loss of the normal discoid 
shape, perturbations in the mechanical and adhesive properties of the cell, and 
alterations in the state of phosphorylation of the erythrocyte membrane skeletal proteins 
[115]. The increased adhesion to endothelial cells in P. falciparum-infected erythrocytes 
is affected by erythrocyte membrane protein1 (PfEMP1) binding to ICAM-1, PECAM-1, 
and enhanced phosphatidyl serine presentation on the red blood cell surface [116]. Our 
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preliminary data shows that only infected erythrocytes take up PF4 and that 
pretreatment with protamine sulfate blocks both entry and activity of PF4 against P. 
falciparum. We therefore hypothesize that initial interaction between PF4 and the 
parasitized erythrocyte is electrostatic and involves binding to negatively charged 
molecules on the surface. Considering that the erythrocyte surface proteins such as the 
glycophorins are rich with sialic acid, we can directly test whether sialic acid is involved 
in the initial binding events by specifically removing it using neuraminidase.
 Another possible explanation for the uptake of PF4, and possibly of smAMPs, is 
the new permeability pathways (NPP). Erythrocytes have a myriad of membrane 
transport proteins including channels and porters that mediate the transfer of solutes in 
and out of the cell. These continue to function after infection of a malaria parasite, and 
undergo further changes some time after invasion to aide in the parasite’s ability to gain 
nutrients [115], such as low molecular weight solutes including sugars, amino acids, 
nucleosides, vitamins, and monovalent anions and cations [117]. Certain inhibitors of the 
NPP have been identified, and would therefore be useful tools in determining if the NPP 
play a role in the uptake of PF4 and smAMPs into parasitized erythrocytes. 
Generating PF4-resistant parasites 
Since AMP-mediated cell death via membrane perturbation does not rely upon a specific 
receptor or intracellular protein target, cellular resistance to compounds that kill through 
membrane perturbation should be difficult to generate. In order to test this hypothesis, 
we will attempt to generate P. falciparum lines that are resistant to PF4. Chloroquine-
resistant parasites (Dd2) will be serially passaged in dilutions of our experimentally 
determined PF4 IC50 (0.25 x IC50, 0.5 x IC50, and the full IC50 concentration) and 
resulting PF4 IC50 values will be determined at each passage.  As a control, parallel 
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cultures will also be exposed to 0.5 x IC50 concentration of pyrimethamine, a well-
established antiparasitic for which resistance has been reported. This will be carried out 
over a time period of at least 6 months. If resistant lines are successfully generated, 
tiling microarrays will be used to determine any genes that contribute to resistance.  
Resistance would indicate that PF4 might not be acting solely via membrane disruption. 
Conversely, if parasites fail to generate resistance to these compounds, this class of 
compounds may have potential as antimalarials that may elicit minimal parasite 
resistance. 
Exploration of the in vivo role of PF4 in malaria 
Due to the conflicting reports of PF4 in the pathogenesis of malaria, further 
investigations are necessary. We report a positive effect that PF4 reduces parasitemia in 
a non-lethal murine model of malaria. Srivastava et al. show that the presence of PF4 
may negatively impact the pathogenesis and prognosis of cerebral malaria. This effect is 
likely through the chemokine domain [62]. As such, we hypothesize that we can harness 
the positive antiparasitic effects of PF4 and avoid exacerbating the cerebral 
symptomology by mutating the N-terminal chemokine receptor-activating loop. A similar 
chemokine-receptor binding and activating structure-function study has previously been 
explored for CCL19/MIP3-β [118], and an endogenous mutant of CCL5/RANTES has 
been discovered to bind to, yet not active two of its receptors, CCR1 and CCR3 [119]. 
Although PF4 does not have a known endogenous receptor, it does interact with the 
alternative splice variant CXCR3B. Cells expressing this splice variant can be used to 
assess whether PF4 containing a mutated N-terminus is no longer able to interact with 
this receptor.  
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After confirming in vitro activity of this mutated PF4 against P. falciparum, we 
would test this in both the severe anemic model of malaria using P. yoelii (which causes 
disease in the peripheral vasculature and organs) versus a model of experimental 
cerebral malaria caused by P. berghei ANKA (which causes pathology in the brain of 
mice). Both PF4 knockout mice [64] and wild-type littermates will be utilized to tease 
apart the effects of endogenous PF4 and the N-terminal chemokine mutant. Mice of 
each genotype will be infected with 1x104 erythrocytes from mice infected with either P. 
berghei ANKA, or P. yoelii. If the exogenously added chemokine-mutated PF4 is able to 
reduce parasitemia and improve survival in the infected mice, this would highly suggest 
that the negative effects of PF4 are in fact mediated through its role as a chemokine. 
This would also support that the direct antimicrobial activity is useful as a potential 
therapeutic, though any potential biologic therapeutic would likely require IV infusion, 
and would therefore not be viable as a prophylactic and may be too expensive to be a 
successful antimalarial. 
4.2 Exploration of the structure-function relationship of antimicrobial chemokine 
activity 
Upon initial discovery that PF4 was active against Plasmodium parasites, we wondered 
if other similar proteins would also be antimalarial. We then hypothesized that the highly 
conserved tertiary structure among chemokines could lead to potential other naturally 
antiparasitic proteins, and first selected chemokines that had demonstrated antimicrobial 
activity. After screening the active portion of the proteins, the amphipathic C-terminal α-
helix, we found that CCL20 was also active against P. falciparum in the low micromolar 
range. We then sought to explore which domains modulate activity against parasites, 
and which domains reduce toxicity against host cell. Surprisingly, we found that 
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hemolysis was ablated only with the intact protein, and that the N-terminal loop 
previously thought to only interact with chemokine receptors, likely is necessary to 
stabilize the whole structure. We seek to further illustrate this concept through the 
following studies: 
Cysteine mutants of PF4 and CCL20 
The key conserved features across all classes of chemokines are the cysteine residues 
present in the N-terminal loop. These two cysteines are either side by side (CC 
chemokines), or separated by any other amino acid (CXC and CX3C chemokines), and 
they form two specific disulfide bonds with two other cysteines in the central β-sheet 
domain (Cys1-3, Cys2-4) [36, 37, 41]. While most of the literature suggests that this N-
terminal loop is only necessary to recognize and activate the chemokine receptor, our 
data shows that this loop also likely stabilizes the overall structure. This is indicated by 
the antimalarial activity being preserved in any PF4 or CCL20 peptide that contains the 
amphipathic C-terminal α-helix, but only the parent proteins are not hemolytic at >5-fold 
the IC50. One way to test this hypothesis would be to remove each disulfide bond, as 
well as both, by replacing the cysteine residues with serine residues in both PF4 and 
CCL20. Another option would be to simply reduce each bond with the addition of DTT or 
TCEP. After destruction of the disulfide bonds, the antimalarial activity, as well as 
hemolytic activity, would be assessed. If our hypothesis is correct, these mutants and 
reduced peptides should retain most, if not all, potency against the parasite, but they 
may show some hemolysis compared to the wild type.  
Generating antimicrobial peptide chimeras 
We show evidence that the intact structure of these antimicrobial chemokines is 
necessary to protect against toxicity to host cells, measured via hemolysis. Therefore, 
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we hypothesize that potent and hemolytic helical antimicrobial peptides may be made 
“safe” by placing them within the chemokine scaffold. Two well characterized AMPs – 
melittin and magainin – will be placed within the PF4 and CCL20 scaffold to determine if 
the activity is retained while hemolysis is ablated. Melittin is a 26 amino acid peptide 
from bee venom, and is a highly lytic molecule. It is comprised of two α-helices with an 
overall bent configuration [120]. Magainins are a class of AMPs from the skin of 
Xenopus laevis frogs with a broad range of activity against microbes [121]. Magainin 2 is 
a 23 amino acid α-helical peptide [31], and surprisingly is much less hemolytic than 
melittin [121]. 
 In order to show that the chemokine scaffold, stabilized by the disulfide bridges 
between the N-terminal loop and central β-sheet domain, is indeed protective, the “long 
peptide” of PF4 and CCL20 will each be replaced by the hemolytic melittin, as well as 
magainin 2. PF4/CCL20 and CCL20/PF4 chimeras will also be generated to show that 
the activity remains within these highly conserved tertiary structures. All chimeras will be 
expressed recombinantly in a secretable Drosophila S2 system. The expected outcomes 
are the PF4/CCL20 and CCL20/PF4 chimeras should retain activity, as the sequence 
itself does not matter, but the overall structure does. The melittin hybrids should be 
potent against P. falciparum (IC50 of melittin ~1 µM), though the hemolytic activity 
should be ablated or greatly decreased. The magainin 2 chimeras should also retain 
activity, implying that the chemokine scaffold may provide an interesting lead for non-
toxic AMP therapeutics. 
Development of peptidomimetics based on the α-helices of antimicrobial chemokines 
In an effort to further understand the interaction of PF4 and CCL20 antimalarial activity 
and generate tools for use for in vivo mouse malaria studies, we will synthesize an array 
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of derivatives based on the α-helical domain of PF4 and CCL20 via standard synthetic 
routes. The underlying principle to the generation of these tool compounds is to increase 
their stability and potency in vitro and in vivo while maintaining low host toxicity. 
Although the full proteins have no hemolysis and IC50s in the low micromolar range, 
utilizing small, synthetic compounds may prove to be more viable for potential malaria 
therapeutics.  We can optimize the antimalarial activity of this molecule using a variety of 
approaches, including the use of D-amino acids, replacement of neutral residues with 
helix promoting non-natural amino acids, stabilization of the helical confirmation to 
render the peptides less susceptible to proteolysis, or the synthesis of helix polymers. 
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